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Abstract
Peripheral inflammation can profoundly alter motivational processes and generate
behavioral symptoms of sickness. Microglia, the innate immune cells of the brain,
orchestrate neuroinflammation and have long been thought to be important for sickness
behavior. However, their precise roles remain obscure due to their complex bidirectional
interactions with neurons in vivo, which regulate how microglia respond to inflammatory
signals and interact with neurons. Neuron-microglia interactions can be at least partially
mediated by various types of G-protein coupled receptors (GPCRs) expressed by
microglia. Here, we generated a microglia specific hM3Gq-DREADD (designer receptors
exclusively activated by designer drugs) mouse line in which hM3Gq is selectively
expressed in microglia, allowing for selective stimulation of calcium signalling in vivo. In
primary cultures, clozapine-N-oxide (CNO) application induced the predicted rise in
intracellular Ca2+ concentration only in hM3Gq-expressing microglia. In vivo, we
validated that tamoxifen-induced hM3Gq expression was highly efficient and specific to
microglia. Systemic administration of CNO (1 mg/kg, i.p.) for 3 consecutive days did not
cause any changes in behavior indicative of sickness behavior, demonstrating that
microglial hM3Gq signaling alone did not cause overt inflammatory response in vivo. We
then challenged these mice with a low-dose lipopolysaccharide (LPS) injection (0.1
mg/kg i.p.) to trigger bona fide sickness behavior. We found that pre-treatment with CNO
for 3 days alleviated classic LPS-induced sickness behavior including, depression of
social interaction and locomotor activity. This treatment also suppressed LPS-induced
upregulation of mRNA of proinflammatory cytokines in the hippocampus. Our work
demonstrates that manipulation of GPCR signalling using this new ‘microglia-DREADD’
mouse line can help to reveal how microglia modulates inflammatory responses and
abnormal behavior in vivo.

Keywords: microglia, neuroinflammation, DREADDs, Lipopolysaccharide, sickness
behaviour, priming, cytokines, peripheral inflammation
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Chapter 1
1. Introduction
1.1 Background
Sickness changes the behaviour and physiology of people: it causes a general feeling of
tiredness, irritability, depressive feelings, and mild cognitive impairment, as well as
physiological changes characterized by fever, anorexia, and fragmented sleep. Despite a
widespread notion that they are meaningless side effects of being sick, these symptoms form a
coordinated physiological adaptation intended to promote recovery of the host (Konsman,
Parnet, and Dantzer 2002). For instance, anorexia serves as a mechanism for the host to be more
specific with its diet as certain bacterial pathogens require nutritional iron for their survival
(Leon-Sicairos et al. 2015). Furthermore, digestion itself is metabolically demanding and
metabolites produced during fasting are beneficial during bacterial infection (A. Wang et al.
2016). On the other hand, under sickness the host adjusts behaviours in a way that benefits their
recovery from infection, for example by rerouting energy reserves (Harrison et al. 2009; Lopes
2014). While sickness is triggered by exogenous causes such as pathogens (bacteria and virus)
and tissue damage (injury), proinflammatory cytokines are the endogenous signals produced by
the immune system responsible for orchestrating sickness behaviour. Proinflammatory cytokines
signal to the brain, trigger secondary inflammatory responses, and consequently recruit neural
circuits relevant to sickness behavior (Robert Dantzer and Kelley 2007). A failure to engage in
sickness behaviours is associated with increased mortality rates (Boltaña et al. 2013; Kluger,
Ringler, and Anver 1975; Lopes 2014). On the other hand, the immune response, when
excessive, may contribute to neuropsychiatric disorders and neurodegenerative disease with
overlapping symptoms with sickness behavior. For instance, accumulating evidence indicate
aberrant actions of cytokines in the pathophysiology of major depression (R. Dantzer et al.
1999).
Microglia, the innate immune cells of the brain, have long been considered as important
cellular intermediates linking inflammatory response and sickness behavior. These cells are
activated by peripheral inflammation and centrally produce cytokines and other inflammatory
molecules (Hanisch and Kettenmann 2007; Nayak, Roth, and McGavern 2014; Ransohoff and
1

Perry 2009; Salter and Beggs 2014), being well positioned to interpret afferent immune signals
and drive ensuing neuroinflammatory response underlying sickness behaviour.
Despite a large number of studies in this area, evidence for the contribution of microglia
to sickness behaviour in vivo is convoluted. This is largely due to the technical difficulty of
specifically targeting microglia in vivo without affecting other cell types. For example,
minocycline, an antibiotics that is known to impair microglial function, inevitably affects many
other cell types, making the interpretation of the data difficult (Garrido-Mesa, Zarzuelo, and
Gálvez 2013). Here I characterized a new transgenic mouse model that express DREADDs
(designer receptors exclusively activated by designer drugs), engineered receptors designed to
respond compounds that in their DREADD-effective doses are inert in other receptors (Nichols
and Roth 2009)specifically in microglia. By using this mouse line, we manipulated microglial
function in vivo and examined its consequence in sickness behavior. In order to outline the scope
of this project, I will first provide a review of research in sickness behaviour, and acknowledge
mechanisms of peripheral immune signalling to the brain. Next, I will focus on microglia in
particular, and discuss properties facilitating communication with neurons and their environment,
particularly GPCRs and calcium signalling. Lastly, I will acknowledge the priming of microglia
and inflammatory stimuli, and suggest the potential of using chemogenetics (DREADDs) to
specifically study microglia functioning in vivo.

1.2. Sickness Behaviour
1.2.1 Pathogen Detection
The signaling cascades leading to sickness behaviour initiate when infectious agents in the
form of bacteria, yeast, or viruses, are detected by peripheral immune cells. These infectious
agents display pathogen-associated molecular patterns (PAMPs) which are recognized by pattern
recognition receptors (PRRs) on the immune cells (McCusker and Kelley 2013). The most
widely studied PRRs are toll-like receptors (TLRs) expressed on the surface of monocytes and
dendritic cells (McCusker and Kelley 2013). The activation of TLRs by infectious agents triggers
the synthesis and release of cytokines and other immune molecules. Among various subtypes of
TLRs, TLR4 is the best characterized. This PRR, in conjunction with the CD14/MD2 complex
recognizes bacterial endotoxin lipopolysaccharide (LPS), leading to the downstream signaling
mediated by myeloid differentiation primary response gene 88 (MyD88). This is followed by
2

nuclear factor kappa beta (NF-kB) transduction pathway, resulting in the eventual production of
proinflammatory cytokines such as IL-1β, TNF-α, and IL-6 (Skelly et al. 2013). These cytokines
are consequently released into circulation by activated immune cells. LPS, a bacterial endotoxin
found in the outer membrane of gram-negative bacteria, is a reliable tool used to promote the
production of proinflammatory cytokines, as well as secretion of nitric oxide, eicosanoids, and
reactive oxygen species (ROS) (Qin et al. 2007; Henry et al. 2008; Poon et al. 2015). LPS
produces many of the types of mediators involved in septic shock (Opal 2010), but sub-septic
doses are commonly used for investigation of immune-brain signalling. Indeed, the dose
response effects of LPS have been well characterized (Skelly et al. 2013).
Importantly, LPS does not infiltrate the blood brain barrier at sub septic doses, nor does it
compromise blood brain barrier integrity (Banks and Robinson 2010; Banks 2006) This makes it
a useful tool for investigating the influence of peripheral cytokines on brain mechanisms, since it
excludes CNS infiltration of circulating monocytes and side effects of a compromised BBB
integrity. Accordingly, LPS is the most popular tool used to assess sickness behavior in rodent
models. This can be measured by using various behavioral tests including withdrawal from social
interactions, inactivity in exploration tasks, anorexia and wasting of body weight, and increased
time of immobility in forces swim tests (FST) and tail suspension tests (TST) (Konsman, Parnet,
and Dantzer 2002).
Since sickness behaviour is a response controlled by the brain, these cytokines must somehow
signal to the brain. The brain has long been viewed as the “immune privileged organ”. However,
this view has been changed by a seminal observation made in 1985 when Block and Smith
discovered immune and nervous system share common ligands and receptors (Blalock, Bost, and
Smith 1985). The first evidence that proinflammatory cytokines are active in the brain was
published in 1986 (Besedovsky et al. 1986) when it was shown that administration of IL-1 to
mice activates the HPA axis, and triggers symptoms of sickness behaviour. It has also been
shown that the central IL-1 administration decreases the preference to the sweet solution
saccharin, impairs food stimulus conditioning, and induces social withdrawal (Crestani, Seguy,
and Dantzer 1991; Kent et al. 1992). Furthermore, cytokine receptors are expressed in the brain,
for example IL-1R1 (Parnet et al. 1994), and cytokine antagonists injected in the brain block the
central effects of peripherally administered cytokines (Kent et al. 1992). It is now known that the
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three classic proinflamamtory cytokines, IL-1β, TNF-α, and IL-6, play necessary roles in
sickness behaviour. The receptors for these cytokines have been shown to be expressed not only
in neurons but also in various non-neuronal cells including microglia, astrocytes, brain
endothelial cells, and perivascular macrophages (S. Rivest 1999). The actions of these cytokines
induce the synthesis of subsequent cytokines within the same cell, as well as other cell types. In
other words, the cytokine signals spread and amplify through a positive feedback mechanism
(Miller et al. 2013). For example, it has been shown that peripheral LPS injection can induce the
upregulation of IL-1β, IL-6 and TNFα first in microglia, followed by astrocyte (Norden et al.
2016). Pharmacological tools which decreases cytokine production prevents both sickness and
depressive-like behavior in mice (O’Connor et al. 2009). Mechanisms which facilitate the
signalling of these cytokines to the brain will be discussed in the next section.

1.2.2 Peripheral Immune Signalling to the Brain
Pathways which facilitate the transmission of cytokine signals to the brain include both
neural and humoral routes (Figure 1.1). To date, four different mechanisms that are not mutually
exclusive have been proposed. Here, I will summarize these mechanisms with relevance to
sickness behaviour.
1. Neural Transmission
Early studies found that immune stimuli are detected by vagal nerve afferents (Figure 1.1,
top), which then relay electrical signals to the nucleus tractus solitaries (NTS) (Bluthe´, Dantzer,
and Kelley 1992). Furthermore, LPS administered intraperitoneal caused a rapid induction of
neuronal activation marker c-Fos, within the NTS (Wan et al. 1993). In line with this, sub
diaphragmatic vagotomy blocks brain-mediated responses to peripheral injections of LPS or IL1β (Fleshner et al. 1998; Simons et al. 1998) (Bluthe et al. 1996b, 1996a). However, in contrast
with this, vagotomy does not block all symptoms induced by LPS; vagotomy has no effect on
LPS-induced fever (Hansen et al. 2000; G. N. Luheshi et al. 2000). Furthermore, the vagus nerve
is likely not the only neural route, since the trigeminal nerve activates neurons within the
hypothalamus modulating feeding behaviour (Malick et al. 2001), while the glossopharyngeal
nerve may also play a role (Romeo et al. 2001). Nevertheless, these studies demonstrate that
neural input to the brain at least partly plays roles in transmitting sickness information from the
periphery to the brain.
4

2. Circumventricular Organs (CVOs)
The circumventricular organs are a group of unique structures which lack the blood brainbarrier, and are thus susceptible to systemic circulation. They include: the subfornical organ
(SFO), vascular organ of the lamina terminalis (OVLT), pineal gland, subcommissural organ
(SCO), median eminence/neurohypophysial complex, the area postrema, and the choroid plexus
(Banks 2006). Macrophage like cells residing in the BBB and circumventricular organs where
the blood brain barrier is leaky respond to peripheral inflammatory signals, by producing
proinflammatory cytokines (Vitkovic et al. 2000). It is believed these locally produced cytokines
then gain entry to the brain via volume diffusion (Figure 1.1, bottom) (N. Quan, Whiteside, and
Herkenham 1998). Indeed, at early time points after i.p. injection of LPS, IL-1β mRNA is
upregulated by cells in the BBB and circumventricular organs (CVOs), while sustained IL-1β
activity in the CNS is derived from glia (N. Quan, Whiteside, and Herkenham 1998). To date, it
has been shown that IL-1β, IL-6, TNFα, IL-10, and other cytokines are secreted from the choroid
plexus and brain endothelial cells (Ning Quan and Banks 2007).

5

Figure 1.1

Figure 1.1 Immune-Brain signalling pathways
The brain and the immune system communicate through different mechanisms. (Top) PAMPs
and cytokines produced in the periphery stimulate vagal nerve afferents which then relay
electrical signals to the nucleus tractus solitaries (NTS) and downstream pathways. (Bottom)
Humoral pathways also involve peripherally produced PAMPs and cytokines, which reach the
brain at areas where the blood brain barrier is leaky. Including the circumventricular organs and
choroid plexus (CP). In the circumventricular organs, PAMPS induce the production of
proinflammatory cytokines, which are believe to gain entry into the brain by volume diffusion or
other mechanisms.
Modified from (Robert Dantzer et al. 2008). Copyright Nature Reviews Neuroscience 2007.
Reprinted with permission.
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3. Saturable Transport Mechanisms
While cytokines are large molecules that do not freely cross the BBB, there is evidence for
saturable transport of cytokines across the BBB (Banks 2006). IL-1β, IL-6, TNFα, and other
cytokines, each have their own transporters (Banks, Niehoff, and Zalcman 2004; Banks, Kastin,
and Durham 1989). Transporters for cytokines are affected by physiological and disease states,
hereby affecting the rate at which cytokines are transported across the BBB (Ning Quan and
Banks 2007; Banks et al. 2001). Limited research has attempted to identify the specific
contribution of these transport systems in cytokine trafficking and consequential cytokine
induced behaviour. IL-1β induced impairment to learning was dependent on BBB transport
(Banks et al. 2001), and LPS-induced dopaminergic neuron damage in the substantia nigra was
dependent on TNFα transport (Qin et al. 2007).
4. HPA-axis Intermediates
Prostaglandins and COX enzymes are important for febrile responses, and these molecules
can also be modulated from the CVOs. For instance, LPS stimulated increase in COX-2
correlates with the febrile responses (Cao et al. 1997), and prostaglandins released from brain
endothelial cells mediate fever induced by LPS (W. Inoue et al. 2002). Lesioning of a CVO close
to the thermoregulatory center of the hypothalamus blocks cytokine induced fever (Zeisberger
and Merker 1992). Activation of IL-1 receptors from macrophages and endothelial cells by
circulating cytokines results in the local production of prostaglandin E2 (PGE2) (Konsman et al.
2004). Specifically, compounds act on neuronal Prostaglandin E receptor 1 (EP1) and
Prostaglandin E receptor 3 (EP3) in the hypothalamic area involved in body temperature
regulation. In particular, the paraventricular nucleus (PVN) and medial preoptic area (MPA)
(Oka et al. 2000; Serge Rivest 2001). These are believed to be the primary mediators of fever
and activation of the HPA axis, since pretreatment with inhibitors of prostaglandin-synthesizing
enzyme COX-2 attenuates these responses (Cao et al. 1997; Parsadaniantz et al. 2000). EP
receptors are prerequisite for LPS-induced activation of HPA axis activity and ensuing febrile
responses (Matsuoka et al. 2003)
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To date, the full contribution of each pathway that facilitates immune-to-brain signalling is
not fully understood. Furthermore, each individual proinflammatory cytokine appears to have
unique contributions to the ensuing signalling cascade in sickness behaviour. For instance, both
IL-1β and TNFα appear to be sufficient to trigger significant sickness characteristics on their
own. IL-1β delivery to the brain that is dependent on neural transmission or any of the humoral
routes triggers characteristic sickness behaviour (Anisman, Gibb, and Hayley 2008; Churchill et
al. 2006; Marquette et al. 2003) (R.-M. Bluthé, Kelley, and Dantzer 2006; Layé et al. 1994). In
this case, knockout of the IL-1R1 receptor in mice prevents characteristic social withdrawal and
anorexia, suggesting IL-1β alone is sufficient to induce sickness. However, in these same mice
with knockout of IL-1R1 (the receptor for IL-1β) sickness behaviour is restored by peripheral
injection of LPS. This suggests that at least one of the other cytokines is also involved in
triggering sickness. Indeed, TNFα delivered i.c.v. replicates the effects of IL-1β, which is then
blocked by a TNFα antibody (R.-M. Bluthé, Layé, et al. 2000), suggesting TNFα is also
sufficient to induce sickness on its own. In fact, TNFα delivery to the brain by numerous routes
induces the full spectrum of sickness (R.-M. Bluthé, Kelley, and Dantzer 2006; R.-M. Bluthé,
Layé, et al. 2000; Churchill et al. 2006; Marquette et al. 2003; Park et al. 2011) as does TNFα
i.p. administration (R. M. Bluthé et al. 1994). In contrast to IL-1β and TNFα, IL-6 by itself does
not induce behavioural symptoms of sickness. It is likely that IL-6 mediates behaviour indirectly
by modulating the levels of IL-1β and TNFα, since sickness behaviour and cognitive impairment
are less noticeable in IL-6 deficient mice, which is correlated with a reduced expression of the
other two cytokines (R.-M. Bluthé, Michaud, et al. 2000, 6; Sparkman et al. 2006, 6).
Furthermore, IL-6 KO mice display less time of immobility in an observation task, weakened
social withdrawal, and less severe anorexia, after i.c.v. administration of LPS or IL-1β, compared
to IL-6 homozygous controls (R.-M. Bluthé, Michaud, et al. 2000). It must also be noted that IL6 does trigger fever and activation of the HPA axis when administered centrally (Lenczowski et
al. 1999). In conclusion, IL-1β and TNFα are necessary for sickness behaviour, but one may
compensate for the other. IL-6 is not necessary for sickness behaviour, but does lessen the
severity of behavioural changes when not present, and is sufficient to trigger febrile responses
and HPA axis activation. Whether neurons or glia cells such as microglia trigger and maintain
ensuing sickness behaviour is unknown (Robert Dantzer et al. 2008).
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1.3 Microglia – the Innate Immune Cells of the Brain
1.3.1 Classic Roles in Inflammation
Microglia, the innate immune cells of the brain, have long been known to detect and
phagocytose infectious agents, engulf apoptotic cells and cellular debris, and promote
inflammation (Kettenmann et al. 2011; Ransohoff and Perry 2009). As such, they have been
implicated in several pathological conditions including Alzheimer’s and Parkinson’s disease,
Prion disease, and ALS (Perry and Holmes 2014; Tang and Le 2016). Emerging research also
implicates microglia in neuropsychiatric disorders (Blank and Prinz 2013). Microglia phenotypes
in the CNS have classically been classified as either M1 or M2. This is a simplified model used
to distinguish microglia between proinflammatory (M1) and anti-inflammatory (M2) dominance.
For example, the M1 microglia are considered proinflammatory, and are recruited to sites of
inflammation where they release proinflammatory cytokines including tumor necrosis factor
(TNF)-α, interleukin (IL)-1β, superoxide, nitric oxide (NO), and reactive oxygen species (ROS).
The M1 phenotype is associated with neurodegenerative disease as well as metabolic disease
(Tang and Le 2016, 1). On the other hand, M2 microglia are classified as either “alternative
activation” or “acquired activation” (Wilcock 2010; Colton 2009). Alternative activation
promotes anti-inflammatory processes and tissue repair and is triggered by IL-4 (Ponomarev et
al. 2007), while acquired activation is also intended to alleviate inflammation but is induced by
phagocytosis of apoptotic cells and exposure to IL-10 (Sawada et al. 1999).
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Microglia have long been considered likely cellular intermediates fueling the response to
systemic inflammation and sickness (Sierra et al. 2014). They are known to drive inflammatory
responses by releasing cytokines and other molecules (Hanisch and Kettenmann 2007; Nayak,
Roth, and McGavern 2014; Ransohoff and Perry 2009; Salter and Beggs 2014), suggesting that
microglia are well positioned to interpret incoming immune signals and help to drive ensuing
neuroinflammation and sickness behaviour. In line with this, when the brain recognizes increased
cytokine levels generated by LPS, microglia responds by robustly increasing production of
proinflamamtory cytokines (Figure 1.2) (Baumann and Gauldie 1994; R. M. Bluthé et al. 1994;
Robert Dantzer and Kelley 2007; G. Luheshi et al. 1996; N. Quan, Whiteside, and Herkenham
1998) (Norden et al. 2016). Furthermore, the microglia inhibitor minocycline prevents LPSinduced cytokine production in the brain (H.-L. Wang et al. 2016; Yoon, Patel, and Dougherty
2012).
Despite the above evidence, the roles that microglia play in controlling sickness behaviour are
not fully understood. This is due in large part to the technical difficulty in targeting microglia in
the living brain without inadvertently affecting other cell types. Moreover, inhibition or
elimination of microglia may disturb microglia-astrocyte-neuronal crosstalk in complex ways. It
has become increasingly clear that microglia function must be studied in vivo, preferentially
using specific techniques which exclusively target microglia and do not modulate the
environment surrounding microglia cells. These cells are highly reactive to signals and cues in
their environment. Indeed, when isolated in culture, microglia display characteristics indicating a
proinflammatory phenotype in the absence of experimental activation (Brawek et al. 2017).

1.3.2 Interactions with Neurons
Under physiological (non-inflammatory) conditions in vivo, emerging evidence show that
microglia dynamically interacts with neurons (Wake et al. 2009). Two-photon imaging in a
double transgenic mouse line simultaneously labelling microglia and neuronal structures
revealed microglia processes make brief, repetitive contacts with presynaptic boutons that last
about 5 minutes. These interactions are experience dependent, as modulation of the physiological
conditions of the brain via binocular eye enucleation or reduction in body temperature, reduced
the frequency of microglia contacts (Wake et al. 2009) In line with this, other research has shown
that microglia interactions with neurons are experience dependent, since altering neuronal
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activity changed functional microglia properties (Tremblay, Lowery, and Majewska 2010; Wake
et al. 2009).
Some of these microglia-neuron interactions are necessary for healthy brain development.
For example, it has long been known that microglia phagocytosis is an important property in
response to brain pathology, however, under healthy conditions the microglia engulfment of
synaptic structures plays important roles in development (Rosa C. Paolicelli et al. 2011; Schafer
et al. 2012). During a period of synaptic maturation in mice, electron microscopy and double
immune-gold labelling identified synaptic proteins within GFP-positive microglia, suggesting
microglia engulfment of synaptic structures. A reduction of specific microglia GPCR CX3CR1
resulted in a reduction in their synaptic pruning and consequential decrease in the ratio of
sEPSC/mEPSC, indicative of immature network connectivity (Rosa C. Paolicelli et al. 2011). In
recent years, other mechanisms of microglia in the regulation of synaptic plasticity have been
identified. This includes the classical complement cascade, which microglia presumably use to
label dysfunctional circuitry (Schafer et al. 2012). Microglia regulation of plasticity also includes
modulation of NMDA receptors or AMPAR, which influence long-term potentiation (LTP) and
long-term depression (LTD) (Zhang et al. 2014; Pfeiffer, Avignone, and Nägerl 2016). Microglia
also affect neural networks through the release of factors with transmitter, trophic or
neuroprotective properties, including TNFα, nitric oxide (NO), or ATP and glutamate
(Kettenmann et al. 2011; Lewitus et al. 2016).
One prominent example of microglia-neuron communication occurs by the release of
brain-derived neurotrophic factor (BDNF) from microglia. In one instance, microglia release of
brain-derived neurotrophic factor (BDNF) increases neuronal tropomyosin-related kinase
receptor B phosphorylation, implicating microglia in another key mechanism of synaptic
plasticity (Parkhurst et al. 2013). This triggered learning-dependant synaptic growth which
correlated with motor learning in a rodarod task (Parkhurst et al. 2013). Microglia BDNF release
has other implications, including the initiation of neuropathic pain/GABAergic signalling (Coull
et al. 2005; Trang, Beggs, and Salter 2011) or neuroprotection (H. Noda et al. 2013).
On the other hand, synaptic pruning by microglia may be associated with brain
pathology. Synapse loss is an early hallmark of AD pathology, and localization and expression of
complement - which acts as a trigger for microglia engulfment -is upregulated in the AD brain
(Benoit et al. 2013). For instance, C1q, the initiating protein of the complement cascade and
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microglia engulfment, is increased and associated with synapses prior to onset of plaque
progression. Complement C3 and microglia complement receptor CR3 also regulates their
phagocytosis, and inhibition of these proteins reduces the number of phagocytosing microglia
and frequency of synapse loss (Hong et al. 2016). Indeed, this microglia engulfment of synaptic
material is dependent on microglia complement receptor CR3, and this is initiated when exposed
to soluble Aβ oligomers (Hong et al. 2016), suggesting microglia engage in excessive pruning of
synapses during AD progression.
Importantly, communication with neurons is bidirectional, as microglia express receptors for
various neurotransmitters and neuromodulators both in the form of metabotropic G-protein
coupled receptors (GPCRs) and ionotropic receptors (Kettenmann et al. 2011). GPCRs are of
particular

interest,

since

they

are

important

modulators

of

neuroinflammation,

neurodegeneration, and behaviour (Kettenmann et al. 2011). Here, I will discuss prominent
GPCRs expressed by microglia, with relevance to calcium signalling and neuroinflammation. I
will also summarize research of microglia calcium response to LPS.

1.3.3 GPCRs expressed in microglia
1. Fraktalkine Receptor (Cx3Cr1)
A large body of literature supports fraktalkine signaling between neurons and microglia
to be a major contributing factor to a wide range of microglia properties (figure 1.3) (Rosa
Chiara Paolicelli, Bisht, and Tremblay 2014) This includes their function during normal
physiology, but also their migration and dynamic surveillance of their environment, neural
plasticity, functional brain connectivity, hippocampal neurogenesis, and behavioural outcomes
(Bachstetter et al. 2011, 1; Milior et al. 2016; Rogers et al. 2011; Zhan et al. 2014). Fraktalkine
signalling involves the soluble ligand CX3CL1, otherwise known as fraktalkine, and the
CX3CR1 receptor exclusively expressed by microglia and monocytes (Milior et al. 2016). The
fraktalkine receptor CX3CR1 is a Gi-protein coupled receptor, which inhibits the production of
cAMP, triggering a variety of intracellular signalling cascades (Chandrasekar et al., 2003).
However, the fraktalkine receptor also mobilizes intracellular calcium (Al-Aoukaty et al. 1998).
Experiments ex vivo using time-lapse confocal imaging showed that microglia motility is
reduced in CX3CR1 deficient microglia (Liang et al. 2009). In these experiments, CX3CR1
deficiency resulted in a significant reduction in microglia process movement both under normal
physiology as well as during tissue injury induced by focal laser application (Liang et al., 2009).
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Several studies have also reported an impairment in synaptic transmission in Cx3Cr1 KO mice
(Hoshiko et al. 2012; Rosa C. Paolicelli et al. 2011; Ueno et al. 2013). At the behavioural level,
Cx3Cr1 KO mice show deficit in motor learning that is paralleled by an impairment in long-term
potentiation (LTP) of synaptic transmission studied in ex vivo, compared to wildtype controls
(Rogers et al. 2011). Animals also failed to show associative learning, and had impairments in
the water maze task. Interestingly, the cognitive deficits observed in CX3CR1 knockout mice
was reversed by administration of IL-1RA into the hippocampus, an antagonist for
proinflammatory cytokine IL-1β (Rogers et al. 2011). In regards to neuroinflammation, it has
been shown with a mouse model of Alzheimer’s disease (AD) that Cx3Cr1 may have protective
roles (Lee et al. 2010). In contrast to this finding, another study investigating neuroinflammation
and AD pathology found an increase in mRNA and protein levels of CX3CR1 to be toxic (Wu et
al. 2013). In both cases, neuroinflammation was assessed by levels of cytokines TNFα and IL1β, which were differentially modulated by expression levels of the fraktalkine receptor. These
opposing roles of CX3CR1 have been replicated in many neuroinflammatory models, showing
either a decrease (Dénes et al. 2008, 1; Donnelly et al. 2011; Fuhrmann et al. 2010) or increase
(Cardona et al. 2006; Cho et al. 2011; Lee et al. 2010) of microglia activity and neurotoxicity.
These results suggest that neuron-microglia signalling mediated by CX3CR1 plays important
roles in neuroinflammation and pathology, but has differential effects on microglia inflammatory
properties which require further investigation.
2. Purinergic Receptors (P2Y)
Metabotropic purinergic receptors mediate phagocytotic function and migration of
microglia. The P2Y6 receptor is linked to Gq/11 proteins and regulates intracellular Ca2+ stores
(Hidetoshi, Makoto, and Inoue 2012, 6). Extracellular uridine-5’-triphpshate (UTP) and its
metabolite uridine diphosphate (UDP), which can leak from damaged plasma membrane, serves
as neuronal damage signal by acting on P2Y6 receptor in microglia (Koizumi et al. 2007).
Research suggests this microglia receptor in particular also mediates astrocyte properties under
LPS-induced inflammatory conditions. In LPS treated co-cultures of microglia and astrocytes,
UDP agonist induced microglia release of nitric oxide. NO release by microglia has been known
to modulate astrogenesis, at least in the hippocampus (Béchade et al. 2011). The P2Y6 induced
release of NO by microglia caused astrocyte apoptosis, herby preventing excessive astrogliosis
during neuroinflammation (Quintas et al. 2014, 6). This inhibitory effect of P2Y6 was abolished
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by blockage of Gq downstream pathway PLC-PKC (Quintas et al. 2014).
The P2Y12 receptor for ATP and ADP, acts as a ‘find me’ signal which triggers
microglia chemotaxis (Honda et al. 2001). Although P2Y12 is a Gi-coupled receptor, it too has
intracellular calcium signalling properties that are dependent on the PLC pathway. Indeed,
studies have confirmed ATP triggers ruffling of microglia processes, and this is dependent on
P13K and PLC intracellular calcium signalling (Irino et al. 2008; Ohsawa et al. 2010), and can
be triggered by neuronal NMDA activation in vivo (Dissing-Olesen et al. 2014). A failure of
phagocytosis or chemotaxis is likely to indirectly modulate levels of neuroinflammation in
certain circumstances (Hidetoshi, Makoto, and Inoue 2012). Importantly, both receptors
discussed here influences the levels of cytokine release following LPS. For instance, both ATP
and UTP supressed release of proinflammatory cytokine TNFα from LPS-stimulated cultured
microglia, with ATP eliciting a stronger effect than UTP (Ogata et al. 2003). Other studies have
shown P2Y-mediated modulation of TNFα, IL-1β, IL-6, IL-12, and IL-10, in LPS-activated
microglia and LPS-activated rat microglia (Lambert et al. 2010; Ogata et al. 2003; Sperlágh and
Illes 2007).

3. Other GPCRs
Microglia express a host of other GPCRs with calcium signalling properties, albeit their roles
are not fully understood.
Glutamate mGluR
Selective activation of Gq-coupled metabotropic glutamate receptor 5 (mGluR5) by (RS)-2chloro-5-hydroxyphenylglycine(CHPG) reduced microglia activation in culture in response to
LPS, marked by reduced ROS, nitric oxide, and TNFα production (Byrnes et al. 2012).
Interestingly, this neuroprotective effect was abolished by inhibitors of PLC and PKC,
suggesting a specific role of microglia calcium signalling in response to neuroinflammation.
Although microglia express a host of other mGluR receptors, including group 2 (mGluR2,
mGluR3) and group 3 (mGluR4-6 and -8), which modulate microglia inflammatory responses,
these are not predicted to modulate Gq-signalling or intracellular calcium signalling in microglia
(Pocock and Kettenmann 2007).
Muscarinic Acetylcholine (mAChRs)
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It is worth noting that a subpopulation (11-16%) of microglia identified with FACS analysis
express muscarinic acetylcholine receptor M3. The M3 receptor agonist carbachol triggered a
transient increase in intracellular Ca2+ (Whittemore et al. 1993). This carbachol-sensitive
population increased in microglia isolated from tissue of mouse models for stroke as well as
Alzheimer’s disease, to 60% and 25%, respectively (Pannell et al. 2016).
Bradykinin
Kinins and bradykinin (BK) are active peptides that are up-regulated in response to
inflammation in the periphery aswell as the central nervous system. In cultured microglia,
bradykinin (BK) (B1 and B2) are linked to Ins(1,4,5)P3 signalling, leading to increased
intracellular calcium and activation of Ca2+-dependent K+channels via Gq signalling (M. Noda et
al. 2003). BK increases microglia motility and induced release of NO and PGE2 (Asraf et al.
2017; M. Noda, Kettenmann, and Wada 2006). However, it can also reduce LPS-induced release
of TNFα and IL-1β (M. Noda, Kettenmann, and Wada 2006).
In conclusion, it is evident that microglia express a host of GPCRs which become activated
by external cues and neurotransmitters, and consequentially modulate microglia properties,
including inflammatory responses. However, the problem remains of studying microglia by
isolating them from brain tissue or culturing procedures, since this transforms them into an
activated phenotype. This especially holds true when analyzing calcium signals, since baseline
calcium levels increase upon isolation. Many of the studies discussed here pointing to the
important of microglia GPCRs, use cultured microglia, meaning we know next to nothing about
the roles of these receptors in “resting” microglia. There is a need for novel techniques which
target microglia signalling without inadvertently modulating the microglia environment.

1.4 DREADDs
New approaches to specifically target microglia without inadvertently modulating the
microglia environment are required. Much of the existing literature on microglia roles is based
on the use of non specific techniques. For instance, minocycline is a tool commonly used to
study microglia function, but its exact mechanism is unknown. Studies indicate MAP kinase and
NFκB inhibition in primary microglia and cell cultures mechanism (Amin et al. 1996;
Nikodemova, Duncan, and Watters 2006). In addition, it likely abrogates microglia expression of
CD11b and MHC II via protein kinase- dependent mechanism (Amin et al. 1996; Nikodemova,
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Duncan, and Watters 2006). However, minocycline is a tetracycline antibiotic which also exerts
non-antiobiotic effects, including anti-apoptotic activities, inhibition of proteolysis, anti-oxidant
activity, and inhibition of several enzyme activities (Garrido-Mesa, Zarzuelo, and Gálvez 2013)
Recently, research has shown significant effects of minocycline on neuronal functioning,
including changes to generation of reactive oxygen species (ROS) and mitochondrial dynamics
(Dai et al. 2017). Based on the reactivity of microglia in vivo, this is likely to inadvertently
modulate their functioning.
Microglia are sensitive enough to detect external changes in the host organism’s
environment. For instance, sensory loss is another environmental factor that changes neuronal
properties in the living brain, and accordingly, alters microglia responses (Tremblay et al. 2012).
Likewise, housing conditions that affect the psychological state of the animal also modulates
microglia functioning. For instance, animals housed in an enriched environment experience a
reduction in levels of neuroinflammation and microglia activation (Briones, Woods, and
Rogozinska 2013; Xu et al. 2016). Inversely, animals housed in an impoverished environment
reveal exacerbated markers of neuroinflammation (Ji et al. 2017). To summarize, nonspecific
techniques which modulate the microglia environment and physiological conditions of the brain
are likely to inadvertently alter microglia functioning.
One possible solution to targeting microglia specifically in the living brain is the use of
DREADDs (designer receptors exclusively activated by designer drugs), engineered muscarinic
receptors which no longer have affinity for acetylcholine (Alexander et al. 2009; Ferguson and
Neumaier 2012). DREADDs can be activated by a number of otherwise inert molecules, such as
clozapine-N-oxide (Whissell, Tohyama, and Martin 2016). Indeed, DREADDs have been used to
tease out novel neuronal functions, and some glia functions (Ferguson and Neumaier 2012;
Scofield et al. 2015; Zhu et al. 2016), but have had limited use in microglia (Grace et al. 2018).
For instance, Ferguson and colleagues used viral vectors to trigger DREADD expression to
specific cell populations in the striatum. They found that transiently decreasing activity of
striatopallidal neurons in rats during repeated amphetamine exposure facilitated the development
of behavioral sensitization (Ferguson and Neumaier 2012). This suggests DREADDs can be an
effective tool to tease out underlying mechanisms of behavioural change. Scofield and
colleagues also used viral vector to express DREADD receptor in astrocytes in the nucleus
accumbens core (NAcore), to reveal a role of glutamate gliotransmission in cocaine seeking
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behaviour (Scofield et al. 2015). Of particular interest for this study, Grace and colleagues also
used viral targeting to express Gq- or Gi- DREADD in spinal microglia in vivo or in vitro under
the CD68 microglia/macrophage promoter. This particular study suggested that in vivo
stimulation of spinal microglia Gq-DREADD is sufficient and necessary for allyodynia induced
by peripheral nerve injury (Grace et al. 2018).
In comparison to viral targeting to express DREADDs, tamoxifen inducible Cre
responsive mice to selectively drive expression of DREADD in microglia is another promising
option. CX3CR1 is a microglia/monocyte specific gene which has successfully been used to
specifically target microglia in the brain (Parkhurst et al. 2013). We choose CX3CR1 to drive
Cre recombinase and DREADD expression, instead of the CD68 marker used in the Grace study,
since CD68 is a microglia marker often associated with activated or inflammatory phenotypes
and elevated antigen presentation (Song, Lee, and Schindler 2011). This poses the risk of
DREADD targeting being biased towards a subset of microglia. Importantly, our chosen
technique avoids the administration of viral vectors, which have previously been shown to
trigger innate immune responses and consequential inadvertent activation of microglia (Sakurai
et al. 2008). DREADDs are engineered to mimic GPCR signalling, which regulates many
important microglia properties, as previously mentioned. DREADDs are a unique tool to
investigate microglia calcium signalling, since neither specific types of GPCRs are expressed
exclusively in microglia, nor are there drugs that can activate only specific subtypes of GPCRs in
microglia to investigate their roles in neuroinflammation.
Our group previously generated mice expressing the h3MDq DREADD in microglia (Fig.
3.1A). Primary microglia cultures obtained from these mice were treated with the active
tamoxifen metabolite 4-OHT (Fig. 3.1B). Our unpublished data show that of Iba1-positive cells
~35% expressed h3MDq detected using the HA tag located at plasma membrane (Fig. 3.1B, C).
In these cultures, only few cells were GFAP positive (astrocytes), and they did not express
hM3Dq (Fig. 3.1D). CNO (3 µM) induced the expected increase in intracellular Ca2+ in the
presence or absence of extracellular Ca2+ indicating the mobilization from intracellular Ca2+
stores (Pei et al. 2008; Urban and Roth 2015). We identified microglia expressing hM3Dq by the
co-expression of mCitrine (Fig. 3.1E, G, right panels, green). Microglia obtained from
CX3CR1CreER -hM3Dq mice but which were not treated with 4-OHT did not respond to CNO, but
still responded to ATP (Fig. 3.1F, H). Predictably, these cells did not exhibit mCitrine, as shown
17

by the absence of green/yellow cell, when imaged with the same parameters as 4-OHT treated
cultures (Fig. 3.1F, H, right panels). These experiments together indicated that hM3Dq
expression in microglia allows for manipulation of Ca2+ signalling pathways by using CNO,
which in our hand could rapidly activate intracellular Ca2+ signalling as previously reported
(Alexander et al. 2009).
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Figure 1.2
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Figure 1.2 Primary Cx3cr1CreER-hM3Dq microglia express inducible DREADD receptors
that trigger Ca2+ signalling in response to CNO. (A) Schematic of tamoxifen-inducible Cre
recombinase driving expression of hM3Dq in cx3cr1+ cells. (B) Representative images of
immunostaining for HA-tag (red) and Iba1 (green) in microglia-enriched culture treated with 4OHT. (C) Quantification of hM3Dq-positive microglia in control and 4-OHT-treated cultures.
***: p<0.001. (D) Representative image of immunostaining for HA (red) and GFAP (green,
astrocytic marker) in microglia-enriched culture treated with 4-OHT. (E-H) Calcium signalling
in Rhod-2 loaded Cx3cr1CreER-hM3Dq microglia cultures. (E) Kinetics of relative Rhod-2
fluorescence in cells in response to 3 µM CNO, 1 mM ATP, or 2 µM ionomycin (left panel) in 4OHT treated cultures in calcium-enriched medium. Snapshot of the imaging field before the
kinetics (right) in transmitted light, green (mCitrine) and red (Rhod-2) channels. (F) Same as (E)
for cultures not treated with 4-OHT. (G) Kinetics of relative Rhod-2 fluorescence in cells in
response to 3 µM CNO, 1 mM ATP, or 10 µM thapsigargin (left panel) in 4-OHT treated
cultures in calcium-free medium. Snapshot of the imaging field before the kinetics (right) in
transmitted light, green (mCitrine) and red (Rhod-2) channels. (H) Same as (G) for cultures not
treated with 4-OHT. At least 3 cultures were imaged for each condition. Kinetics from all cells in
the imaging field were analyzed. *: p<0.05.
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Based on this preliminary data, the hM3Dq-microglia mouse model is a promising tool to
investigate microglia responses in sickness behaviour. To this point, we aimed to investigate the
consequences of hM3Dq signalling in microglia in vivo under healthy condition and during
inflammation.

1.5. Rationale, Hypothesis, Aims
1.5.1 Rationale: Microglia roles in sickness
Peripheral inflammatory driven immune signals induce sickness behaviour by triggering a
secondary neuroinflammatory response in the brain. Microglia, the immune cells of the brain,
orchestrate neuroinflammation and have long been thought to be important for sickness behavior.
However, their precise roles in sickness behaviour remain obscure due to their reactivity to the
physiological conditions of the brain as well as their complex interactions with neurons in vivo.

1.5.2 Hypothesis
Microglia GPCR signalling contributes to neuroinflammatory and sickness behaviour during
systemic inflammation.

1.5.3 Aims
1. Complete characterize of the Cx3cr1CreER-hM3Dq mice and determine potential
microglia specific expression of hM3Dq, and CNO-mediated Ca2+ dynamics.
2. To investigate the behavioural and neurochemical changes that occur in response to
microglia-hM3Dq signalling in vivo.
3. To investigate the behavioural and neurochemical changes that occur in response to
microglia-hM3Dq signalling in vivo following PS-induced systemic inflammation.
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Chapter 2
2. Materials and Methods
2.1 Animals
CX3CR1CreER mice (Jackson Laboratory, B6.129P2(Cg)-Cx3cr1tm2.1(cre/ERT2)Litt/WganJ)
expressing tamoxifen-activated Cre-recombinase and EYFP in microglia in the brain (Parkhurst
et al. 2013), were obtained from Jackson Laboratories. R26-hM3Dq/mCitrine (Jackson
Laboratory, B6N;129-Tg(CAG-CHRM3*,-mCitrine)1Ute/J) mice expressing a Cre responsive
hM3Dq N-terminal HA-tag were previously described (Zhu et al. 2016) and they were gently
donated by Brian Roth. To produce mice expressing microglia-specific hM3Dq, CX3CR1CreER
mice were crossed with R26-hM3Dq/mCitrine, and subsequently treated with tamoxifen. We
wait >30 days after tamoxifen injection, based on the fact that microglia and other CX3CR1+
cells have substantially different turnover rates and regenerate from different precursor
populations (Fogg et al. 2006; van Furth and Cohn 1968). We expect that microglia would
undergo recombination that persists once tamoxifen has ceased (Parkhurst et al. 2013). In
comparison, peripheral CX3CR1+ cells would initially express hM3Dq but subsequently be
replaced by bone marrow derived Cx3cr1- cells not forgoing recombination. All mice shown are
male, and 3-5 months of age at the time of experimentation. All procedures were conducted in
accordance with the guidelines of the Canadian Council of Animal Care and approved by the
University of Western Ontario Animal Use Subcommittee (protocol 2016-103 and 2016-104).
The study also complied with the ARRIVE guidelines (Animal Research: Reporting in Vivo
Experiments). Animals had access to food and water ad libitum, and were maintained on a 12
h/12 h light-dark cycle.

2.2 Tamoxifen
Tamoxifen (Sigma, cat#T56648) was dissolved at 100 mg/ml in 10% ethanol/90% corn oil by
heating to 55 °C and vortexing. Aliquots were kept at -20 °C for no more than 1 week.
Immediately before use, the aliquots were diluted to 20 mg/ml in corn oil and injected 4 µl/g
body weight. To induce DREADD expression, tamoxifen (80 mg/kg i.p.) was injected once per
day for 5 consecutive days. For cell culture assays, tamoxifen active metabolite 4hydroxytamoxifen (4-OHT, Sigma, cat#H6278) was used instead of tamoxifen 4-OHT was
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dissolved in 100% ethanol to final concentration 14 mM, and stored aliquoted at -80 °C. Before
use, the aliquots were diluted to 5 µM in the culture medium. E. coli 0111:B4 LPS (SigmaAldrich, 297-473-0) was aliquoted at 5 mg/ml and stored at -80 °C until used. Clozapine NOxide (CNO, Tocris, cat#4936) was dissolved to 1 or 5 mg/ml in dimethylsulfoxide (DMSO)
and stored aliquoted at -20 °C. Calcium dye Rhod-2 AM (Abcam, cat#ab142780) was diluted to
1 mM in DMSO and stored aliquoted at -20 °C. Store-operated Ca2+ inhibitor (SOCE) SKF96365 (Santa Cruz, cat#130495-35-1) was diluted in water.

2.3 Primary Microglia Cultures
Mixed glia cultures were prepared from the P0-P2 mice following established procedure
(McCarthy and Jean De Vellis 1980)(McCarthy and Jean De Vellis, 1980) with small
modifications. Briefly, extracted forebrains were dissociated in DMEM/F12, supplemented with
1 mM KCl, 10% heat-inactivated fetal bovine serum (both ThermoFisher) and 1×
penicillin/streptomycin (Sigma). Cells were plated on 75-cm2 tissue culture flasks coated with
poly-D-lysine and incubated at 37 °C in 5% CO2 atmosphere. The culture medium was changed
after 3 days and then every 5 days until confluency (12–18 days in vitro).
To obtain pure microglia cultures flasks of mixed glial cultures were shaken at 200 rpm
for 2 h at 37 °C. Floating microglia were collected by centrifugation (380g for 10 min), and
seeded at ~1×105 cells/ml on poly-D-lysine coated dishes containing 50% old/50% new media.
In the next day culture medium was supplemented with 5 µM 4-OHT and incubated for 48 h for
optimal induction of hM3Dq expression. Approximately 5×105 cells were obtained per brain
used.
Immunocytochemistry was done on microglia plated on glass coverslips as described
previously (Ostapchenko et al. 2013). After 48-hour incubation with 5 µM 4-OHT or vehicle,
cultures were rinsed with ice-cold PBS and fixed with 4% paraformaldehyde (PFA) in PBS.
After permeabilization with 0.5% Triton X-100 and blocking with 5% bovine serum albumin
(BSA)/0.1% Triton X-100, cultures were incubated with primary antibodies (anti-HA-tag for
hM3Dq, BioLegend, cat#901501; anti-Iba1, marker for microglia, Abcam, cat#ab5076; antiGFAP, marker for astrocytes, Abcam, cat#ab7260) overnight at 4 °C, followed by 1-hour
incubation with Alexa Fluor 555 goat anti-mouse (1:1000, cat#A32727) and Alexa Fluor 633
goat anti-rabbit (1:1000, cat#A-21070, both Thermo Fisher) secondary antibodies and Hoechst
33342. Coverslips were then mounted on glass slides using Immumount (Thermo) medium and
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imaged using an FV1000 confocal microscope (Olympus) equipped with a 20x/0.75, 30x/1.05 or
60x/1.35 objective. At least 3 cultures were imaged for each condition and staining markers, with
at least 6 images randomly taken over a coverslip. Images were analyzed using ImageJ (NIH,
Bethesda, MD) Cell Counter plugin.

2.4 Electrophysiology
Male mice were deeply anesthetized in a chamber saturated with isoflurane, and once spinal
reflexes were absent, were decapitated. The brains were quickly removed and placed in ice cold
slicing solution containing (in mM) 87 NaCl, 2.5 KCl, 0.5 CaCl2, 7 MgCl2, 25 NaHCO3, 25 Dglucose, 1.25 NaH2PO4 and 75 sucrose, constantly bubbled with 95% O2/5% CO2. Coronal
brain sections (300 µm) were cut using a vibratome (VT-1200, Leica Biosystems). Hippocampal
regions were trimmed and transferred into an incubation chamber containing artificial
cerebrospinal fluid (aCSF) consisting of (in mM) 126 NaCl, 2.5 KCl, 26 NaHCO3, 2.5 CaCl2,
1.5 MgCl2, 1.25 NaH2PO4 and 10 D-glucose, saturated with 95% O2/5% CO2 and maintained
at 35 °C. Slices were recovered at this temperature for 45 min, and thereafter were kept at room
temperature. For electrophysiological recordings, slices were transferred to a recording chamber
superfused with aCSF (1.5-2.0 ml/min, 27-30 °C). Recording pipettes were made from
borosilicate glass (BF120-69-15, Sutter Instruments) pulled in a horizontal puller (P-1000, Sutter
Instrument) with an open tip resistance between 3.0-5.0 MΩ, filled with an internal solution
containing (in mM) 116 K-gluconate, 8 KCl, 1 K2-EGTA, 10 HEPES, 2 MgCl2, 4 K2ATP and
0.3 Na3GTP. In some experiments, BAPTA-K4 (10 mM) was added to the internal solution.
Osmolarity was 285-290 mOsm, pH 7.2-7.4. CA1 pyramidal neurons were visually identified for
their large cell soma using an upright microscope equipped with infrared differential interference
contrast optics (BX 51WI, Olympus). In voltage-clamp configuration, postsynaptic neurons were
held at −68 mV and EPSCs were pharmacologically isolated with the GABAA receptor
antagonist picrotoxin (100 µM) and the glycine receptor antagonist strychnine (0.5 µM) added to
the aCSF. Tetrodotoxin (TTX, 0.5 µM) was added to block voltage gated Na+ channels to record
miniature excitatory postsynaptic currents (mEPSCs). Access resistance was monitored
throughout the recordings and if the value exceeded 20 MΩ the recordings were rejected.
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2.5 Immunohistochemistry
Initial immunohistochemistry experiments in primary cultured microglia was performed by
Valeriy Ostapchenko. Quantification of Iba-1+ microglia/hM3Dq+ cells was performed by
Muhammed Al-Onaizi. Subsequent experiments re analyzing Iba1+/hM3Dq+ cells, and
microglia morphological dynamics, used the same perfusion and slice preparation techniques, as
follows. Mice were initially perfused with 200mL of cold PFA, and mouse brains were extracted
from mice injected with tamoxifen or vehicle as described previously (Ostapchenko 2015). After
incubation in PFA for 24 h, brains were sectioned using a VT 1200 S vibratome (Leica). Staining
for Iba1 (1:1000, WAKO, cat#CTK6675), HA (1:1000, BioLegend, cat#901501), GFAP
(1:1000, Abcam, cat#ab7260) or NeuN (1:1000, Cell Signalling, cat#D3S3I) was performed as
described previously (Kolisnyk et al. 2016) using Alexa Fluor 555/633-tagged secondary
antibodies (ThermoFisher) and Hoechst 33342. Sections were mounted on glass slides using
Fluorescent-G mounting medium (Electron Microscopy Sciences, cat#17984-25) and imaged
using an SP8 confocal microscope (Leica) equipped with a 20x/0.75 dry or a 40x/1.3 oil
objective. At least 4 forebrain sections were imaged for each animal for each condition, with at
least 6 fields imaged for each section. Images were analyzed using ImageJ Cell Counter plugin.

2.6 Peripheral Injection of LPS
In all studies using LPS, unless otherwise indicated, adult mice received a single (0.1 mg/kg,
i.p) injection of either saline or LPS (from a 5 mg/mL stock). This dose of LPS was chosen
because it is the minimum effective dose to elicit proinflammatory cytokine response and
sickness behaviour in mice (Berg et al. 2004). In order to assess microglia morphology, mice
were injected with 0.5 mg/kg i.p. LPS (0111:B4, 5 mg/mL), which is a dose previously used to
study microglia dynamics (Hines et al. 2013) (Wohleb et al. 2012).

2.7 ELISA
Levels of IL-6 in plasma was determined using mouse IL-6 ELISA kit (ThermoFisher,
cat#KMC0061). Plasma was defrosted on ice and diluted 4× with kit-supplied standard diluent
buffer (SDB). ELISA procedure was performed according to manufacturer’s instructions. Data
were obtained from 4 animals for each condition. Data was analyzed using Two-way ANOVA
and sidak’s post hoc analysis.
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2.8 RNA Extraction and qPCR
Total RNA was extracted from the hippocampus and spleen using Aurum Total RNA mini-kit
(Bio-Rad, cat#732-6870) and phenol/chloroform mix (Invitrogen, cat#15593-031). cDNA was
synthesized from 2 µg of RNA using High Capacity cDNA RT kit (Applied Biosystems,
cat#4368814). qPCR was performed in a CFX96 Real-time system (Bio-Rad) using SensiFAST
SYBR NO-ROX kit (Invitrogen, cat#BIO-98020) and specific primer sets (shown below) for IL6, TNF-α, IL-1β, iNOS, COX-1, COX-2, BDNF, IL-1RA, IGF-1, and C1q, and RPL13a as the
housekeeping gene. Data were analyzed using the comparative threshold cycle (Ct) method and
results were expressed as fold difference from the control group identified (vehicle-saline or
vehicle-LPS). Data was analyzed using a student’s t-test. Specific oligonucleotide primers for
qPCR are as follows: TNFα, forward, 5’- CTTCTGTCTACTGAACTTCGGG-3’, reverse, 5’CAGGCTTGTCACTCGAATTTTG- 3’; IL-1β, forward, 5’- ACGGACCCCAAAAGATGAAG3’;

IL-6,

forward,

5’-

reverse,

GATGCTACCAAACTGGATATAATCAG-3’,

5’-

CTCTGAAGGACTCTGGCTTTG-3’; iNOS, forward, 5’- AAGATGGCCTGGAGGAATGC3’,

reverse,

5’-

BDNF,

TGCTGTGCTACAGTTCCGAG-3’;

forward,

5’-

TCTTTTCCGAGGTTCGGCTC-3’, reverse, 5’- CAGCCTACACCGCTAGGAAG-3’; COX-1,
forward,

5’-

CATTGCACATCCATCCACTCC-3’,

reverse,

5’-

ACAGGATTGACTGGTGAGGG-3’; COX-2, forward, 5’- GATGACTGCCCAACTCCC-3’,
reverse,

5’-

AACCCAGGTCCTCGCTTA-3’;

CTTGGCAGTGTCCTGGTGAC-3’, reverse,
forward,

5’-

C1Q,

5’- CATGGTGTCCCTGCCTCC-3’;

GGAGATGTACTGTGCCCCAC-3’,

TAGGGACGGGGACTTCTGAG-3’;

forward,

IL-1RA,

reverse,
forward,

5’IGF1,
5’5’-

AACCAGCTCATTGCTGGGTACTTA, reverse, GCCCAAGAACACACTATGAAGGTC-3’;
and

RPL13a,

forward,

5’-

CTGCCCCACAAGACCAAGAG-3’,

reverse,

5’-

GGACCACCATCCGCTTTTTC-3’.

2.9 Microglia Morphology Quantification
Iba-1 was imaged using EVOS FL Auto 2 Imaging System (Thermo Fisher) and subsequently
analyzed using ImageJ as previously described (Milior et al. 2016). Briefly, 4 representative
images of the hippocampus of each animal were taken, of which 5 cells were chosen for analysis
by an investigator blind to the treatment. Criteria for selection included the cells being entirely
within the boundaries of the image and fully in focus. For each cell, the image was first set to
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binary colour scheme, after which both the outermost points of each process, and also soma were
traced around. The morphological index of the cell was determined as ratio of the soma area and
the full arborisation. Twenty cells from each animal for each condition were analyzed and their
averages were compared using GraphPad 7.0 (Prism) and Two-way analysis of variance
(ANOVA), with sidak’s post hoc analysis.

Figure 2.1

Figure 2.3 Technique for microglia quantification using evos
In order to investigate potential effects of CNO, LPS, or both, on microglia morphological
dynamics, Iba-1 was imaged using EVOS FL Auto 2 Imaging System (Thermo Fisher) and
analyzed using ImageJ. First, a representative image was taken from the Radiatum region of the
hippocampus. Next, representative images were set to binary using Image J software (shown in
1). (2) Individual representative cells that were entirely within image boundaries and in focus
were chosen by an investigator blind to the treatment. (3) The soma of identified cells was traced
with the free hand tool and measured. (4) The outermost extremeties of the cell’s processes were
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traced around with the free hand drawing tool and measured. This was repeated for 5 cells, for 4
different images per animal, yielding measurements for 20 different cells per animal.
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2.10 Behaviour Experiments
For all behavioural experiments, mice were injected with vehicle or CNO (1.0 mg/kg, i.p.; 3
consecutive days) 30 minutes before their trial. All experiments were completed with male
(Cx3cr1CreER-hM3Dq) mice during the light period (between 10:00 and 16:00 ). Mice were 3-6
months old at the time of experiments. Prior to all behavioural tests, the mice were allowed to
adapt to the test room for 30 min. All behaviour experiments are performed by investigators
blind to the treatment. Littermate mice were randomly assigned for experimental groups.
Behaviour experiments were completed in the following sequence: series one, open field (day 1),
open field (day 2), social preference (day 3); series two, open field (day 1), open field (day 2),
social memory (day 3); series three, light-dark box (day 1), elevated-plus maze (day 2), forced
swim-test (day 3); series four, object recognition (day 3); series five, olfaction test (day 3). The
same cohort of mice was used throughout a single series. A different cohort of mice was used for
each different series.

2.11.1 Social Preference
Sociability was assessed as previously described (Kwon et al. 2006). Briefly, testing was done
in a three-chambered apparatus (15×90×18.5 cm divided into three chambers of 15×29 cm and
separated by dividers with a central 3.8×3.8 cm door) (shown in Figure 2.4) (Med Associates, St.
Albans, VT, USA) that offers the subject a choice between a social stimulus and an object. To
assess sociability, mice were first habituated for 10 min to the 3-chamber apparatus and two
empty holed acrylic cups at each end (Leite et al. 2016). Mice were then locked in the center of
the chamber for 5 min, during which a novel object (green lego block) was placed under the cup
at one end, and a juvenile intruder of different background was placed under the cup at the other
end. Time spent investigating the object and the intruder was recorded by an investigator blind to
the treatment. Investigation was tracked when mice were sniffing a chamber within 5-cm radius
(determined by Any-maze tracking software, Stoelting Co.). After the experiment, videos from
each trial were re-watched and manually scored when mice sniffed through the holes of the
chamber, by an investigator blind to the treatment. Performance is graphed according to the
manual scoring, which on average differed by <3% compared to Any-maze tracking. In baseline
experiments, data were analyzed using student’s t-test. In LPS experiments, data were analyzed
using repeated measures Two-way ANOVA, and Sidak’s post hoc analysis.
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Figure 2.2

2

3
1

Figure 2.4 Social preference assay
Shown is the three-chambered apparatus (15×90×18.5 cm divided into three chambers of 15×29
cm and separated by dividers with a central 3.8×3.8 cm door) (Med Associates, St. Albans, VT,
USA) where all social preference experiments were carried out. Briefly, animals were first
habituated to the chamber for 10 minutes, with access to all chambers, including 1,2 and 3, with
empty see through holed acrylic cups in chamber 2 and 3. Animals were then locked in chamber
1 for 5 minutes while the chambers were filled with either a novel juvenile intruder (2) or a lego
block (3). Time spent investigating chamber 2 and 3 within a 5-cm radius around the cups was
recorded by an investigator blind to the treatment.
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2.11.2 Social Memory
Social memory was completed as previous described (Prado et al. 2006). Briefly, mice were
singly housed 4 days prior to the experiment to establish territorial dominance. To test social
interaction, a juvenile intruder was placed in the test subject’s home cage, under a transparent
acrylic chamber allowing for olfactory investigation. Interaction was recorded as sniffing the
cage within 5 cm (defined by Any-maze tracking software). Immediately before testing, mice
were habituated to an empty acrylic chamber for 10 min; a juvenile intruder was then placed
inside for a 5-min test period, followed by 3 consecutive trials with 15 min inter trial intervals.
Prior to trial 5, to assess social memory, a new juvenile intruder was used. Time of investigation
was manually recorded by an investigator blind to treatment. Time the mice spent sniffing the
juvenile intruder during each of the 5 trials were compared using Repeated measures Two-Way
ANOVA, and multiple comparisons test to compare trials.

2.11.3 Open Field
Open field activity was assessed as previously described (Janickova Helena et al. 2017;
Martins-Silva et al. 2011) with small modifications. VersaMax Tracking System (X-Y and Z
sensors) automatically recorded activity of mice in an open field box (40.64×40.64 cm2)
(Omnitech Electronics Inc., Columbus, USA) divided into 4 equal quadrants separated by acrylic
plexiglass, without an investigator present in the room. Two mice were placed in the lower left
corner, of the bottom left box and top right box, respectively. The task was completed on two
consecutive days with the exact same criteria. Locomotor activity is expressed as the total
distance (cm) that mice travel during the trial, in comparison, time in center was recorded as the
total time in seconds that mice spend within the inner (8×8 cm2) region of their box. All open
field data (locomotor activity and time in center) are expressed as a sum of the first 60 min of the
trial. For all open field experiments assessing baseline activity, a repeated measures two-way
ANOVA, with sidak’s post hoc analysis was used. For all open field experiments assessing LPSinduced neuroinflammatory behaviour, a student’s t-test was used.

2.11.4 Light-Dark Box
The following three behaviour experiments were performed by Sara Matovic of the Inoue
Lab. The light-dark test was performed similar to previously described (A. M. Depino 2015;
Amaicha Mara Depino, Tsetsenis, and Gross 2008). Mice were placed under the hole of the dark
enclosure, and allowed to freely move for 5 minutes. Mice were automatically recorded with
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VersaMax Tracking System (X-Y and Z sensors) in an open field box (40.64×40.64 cm2). A dark
enclosure (Opto-Varimex-5 Light/Dark Box, 0150-LDB) was placed in the top half of the open
field. Data are represented as total time the mice spend in the half without the dark enclosure.
The crossover measurement – which records time in one region until the animals full body enters
the other region - was used in order to prevent tracking of light side activity when the mice only
have their head sticking out of the dark box Figure 2.7) Student’s t-test was used for analysis.

2.11.5 Elevated Plus Maze
To assess anxiety-like behaviour, the elevated plus maze was performed as previously
described. Additional details are as follows, a maze with two open arms and two enclosed arms
(open arms: 30×5 cm, surrounded by a 0.5-cm-high border; closed arms: 30×5 cm, surrounded
by 19-cm-high walls; (Med Associates Inc., St Albans, USA) was used (Figure 2.8). Mice were
placed on the central platform facing an open arm and were allowed to freely explore for 5 min.
Any-maze tracking software (Stoelting Co.) recorded locomotor activity during the test. Total
time mice spend in the open arms of the maze was compared using a Student’s t-test.

2.11.6 Forced Swim Test
Forced swim test was completed similarly to previously described procedure (Beraldo et al.
2015) A plastic beaker (diameter, 15 cm; height, 25 cm) filled with 16 cm of water at 25 ℃ was
placed in the center of a table underneath a camera with Any-maze software. Mice were placed
in the bucket of water, and immobility/mobility was recorded for 6 min. The initial 2 min of the
trial were discarded to account for the habituation phase. Data expressed as time of immobility
during last 4 min was analyzed using Student’s t-test.

2.11.7 Object Recognition
In order to control for potential recognition deficits, a design similar to social memory was
used (Prado et al. 2006). The time spent sniffing a holed acrylic chamber (within 5cm; defined
by Any-maze software) was measured. Initially, a 10-min habituation phase was given where the
mice explored an empty chamber in the test cage. For testing, a green rectangular shaped lego
block was placed inside the chamber, and sniffing was measured during four consecutive 3-min
trials with 10-min intervals. Prior to the 5th trial, an unfamiliar object (a red prism lego block)
was placed under the chamber. Results are graphed as time (seconds) the mice spent
investigating the chamber during each trial, and analyzed using Two-Way ANOVA, and multiple
comparisons test to compare trials.
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2.11.8 Olfaction Test
Olfaction was assessed as previously described (Prado et al. 2006). Briefly, to test olfactory
deficits mice were exposed to the same scent (vanilla extract) for four consecutive 3-min trials
with 10-min intertrial intervals. A 5×5 cm2 paper towel was soaked with 3 large drops of vanilla
extract and placed in a small petri dish with several small holes in its cover to allow for olfaction
but prevent physical interaction with the paper towel. The paper towel was replaced with a newly
soaked one before each trial to maintain a consistent level of scent during each trial. Prior to trial
5, the paper towel was instead soaked with caramel extract. Time of sniffing was manually
recorded by an investigator blind to treatment. Time spent sniffing during each trial was
compared using Two-way ANOVA and multiple comparisons test was used to compare trials.

2.12 Statistical Analysis
All statistical analyses were performed using GraphPad software (Prism). For two-group
comparisons, Student’s unpaired t-test was used. For multiple group comparisons, two-way
ANOVA was used with Sadik’s or Tukey’s post hoc test. Data are expressed as a mean +/standard error of the mean (S.E.M.).
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Chapter 3
3. Results
3.1 hM3Dq is expressed selectively in Iba1+ microglia in
CX3CR1CreER-hM3Dq mouse brain
We first characterized tamoxifen-inducible hM3Dq expression in microglia by using
immunohistochemistry against HA (hM3Dq N-terminal tag) and the microglia marker Iba1. We
found no background expression of HA in the absence of tamoxifen injection (Fig. 3.2.1A). In
contrast to the more restricted expression in cultures, tamoxifen treatment caused widespread HA
expression in mouse forebrain when examined at 10 day (Compare Fig. 3.2.1A and B) and 3
months (Compare Fig. 3.2.1A and C) after tamoxifen administration. Indeed, because of the low
turnover of microglia in the mouse brain (Füger et al. 2017), we detected significant labeling of
h3MDq even after 12 months after tamoxifen treatment (not shown). To avoid expression of
h3MDq in other myeloid-derived cells for our experimental manipulations, we waited 1 month
after tamoxifen treatment of mice before performing experiments, so that populations of
peripheral myeloid-derived cells could turn over, as previously described (Parkhurst et al.
2013)(Fogg et al. 2006; van Furth and Cohn 1968).
In order to determine the selectivity of h3MDq expression in vivo, we stained
hippocampal brain sections with HA antibody and markers of microglia (Iba1, Fig. 2D), neurons
(NeuN, Fig. 3.2.2E) or astrocytes GFAP (Fig 3.2.2F). These experiments demonstrated that
hM3Dq is expressed mainly at the cell surface of microglia, with no co-localization with NeuN
or GFAP. At 3 month after tamoxifen injection, 96.3% (n=696) of HA-positive cells were also
positive for Iba-1, and 87.0% (n=770) of Iba-1 positive cells were HA-positive (Fig. 3.2.2G, 3
different animals). We inspected other brain regions and also found widespread labeling of HA
consistent with microglia morphology (not shown). These experiments together demonstrate that
microglial hM3Dq is functional and expressed in most microglia in the brain, allowing the
manipulation of Ca2+ signalling in vivo.
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Figure 3.1.1

Figure 3.1.1 Tamoxifen-inducible Cre-mediated expression of hM3Dq is specific to
microglia.
(A -C) Representative confocal images of hippocampus from Cx3cr1CreER-hM3Dq mice not
treated with tamoxifen (A), and following 10 days (B) and 3 months (C) after tamoxifen
injections.
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Figure 3.1.2

Figure 3.1.2 Tamoxifen-inducible Cre-mediated expression of hM3Dq is specific to
microglia.
The initial experiment and quantification (G) was performed by Muhammed Al-Onaizi, who also
contributed representative images shown in F. (D-F) Representative confocal images showing
distribution of hM3Dq marker HA (red) in tamoxifen-treated Cx3cr1CreER-hM3Dq mouse brain
against (D) Iba1+ microglia (green), (E) NeuN+ neurons (green) and (F) GFAP+ astrocytes
(green). Right panels show zoomed images of left panels with Hoechst nuclear stain (blue). (G)
Quantification of cells double-labelled for Iba1 and HA (yellow), Iba1 alone (green), and HA
alone (red).
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3.2 Stimulation of Ca2+-signalling in microglia does not cause
overt behavioural change, alterations in mRNA gene expression
or synaptic transmission
Recent studies suggest roles of microglia in modulating a number of neuronal functions
(Dissing-Olesen et al. 2014; K. Inoue et al. 2009; Milior et al. 2016) and behavior (Milior et al.
2016) (Corona et al. 2010; Zhan et al. 2014) (Rogers et al. 2011). Thus, we first examined the
behavioral consequences of activating hM3Dq in microglia of adult mice. We conducted a series
of behavioral analyses over 3 days, where each day mice were treated with CNO (1.0 mg/kg,
i.p.) or vehicle (0.5% DMSO in saline) 30 min prior to individual behavioral tests (Fig. 3.3.1A).
Open field test conducted on two consecutive days (Day 1 and 2) to determine locomotor activity
showed significant effects of Day on the total distance travelled (Fig. 3.3.1B), revealing expected
habituation to the task on the 2nd day (F(1,28)= 5.947, p= 0.0213). However, there was no effect of
CNO (F(1,28)=3.066, p=0.9956) or interaction between CNO treatment and time (F(1,28)= 0.2367,
p= 0.6304). Similarly, time in center (Fig. 3.3.1C) was affected by the day of the experiment, but
not by CNO (time: F(1,28)=62.94, p<0.0001; CNO: F(1,28)=1.045, p = 0.3153; interaction:
F(1,28)=1.031, p = 0.3187). These results suggest that activation of microglial hM3Dq did not
affect locomotor activity, habituation to the task or anxiety-like behavior measured by time spent
in the center of the box.
On Day 3 we tested social behaviour using 3-chamber social preference task (Fig.
3.3.1D). While the mice showed predicted preference to a conspecific over novel object
(Vehicle; t-test (38)= 8.4444, p<0.0001; CNO; t-test (40)= 8.361, p<0.0001), CNO did not affect
social interaction (t-test (39) = 0.9272, p=0.3595). Using a separate cohort of mice, we also
examined social memory after 3 days of CNO or vehicle treatment (Fig. 3.3.1E). Both CNO and
vehicle treated animals did not differ in interaction with the juvenile mice (F(1,28)=0.3988,
p=0.5328). As expected, there was a significant effect of trial on time of interaction, suggesting
mice remember the initial intruder (F(4,112)= 21.84, p<0.0001). These results suggested that
activation of microglial Ca2+ signaling did not affect social behaviour. Using a third cohort of
mice, we found that CNO did not affect anxiety-like behavior when tested using a light-dark box
[Day 1, t-test(15)=0.1398, p=0.8907; (Fig. 3.3.1F)] and elevated plus maze [Day 2, ttest(15)=0.007498, p=0.9941; (Fig. 3.3.1G)]. We also did not detect any effect of CNO in
depression-like behavior using the forced swim test [Day 3, t-test(15)=0.4787, p=0.6391; (Fig.
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3.3.1H)]. As a control experiment, we injected mice for 3 consecutive days then assessed
olfactory memory (Fig. 3.3.1I) and object memory (Fig. 3.3.1J). Similar to our social memory
results, we found that there was a significant effect of trial on time of smelling (F(4,56)=24.25,
p<0.0001) and object investigation (F(4,52)=19.74, p<0.0001), but there were no effect of CNO or
interaction in olfaction (CNO: F(1,14)=0.004324, p=0.9485; interaction: F(4,56)=1.156, p=0.3403),
or object recognition (CNO: F(1,13)=0.1905, p=0.6697; interaction: F(4,52)= 0.8272, p=0.5139).
Together, these experiments suggest that activation of Ca2+ signalling in microglia does not
cause any sort of sickness behavior nor does it affect performance in a number of behavioral
tasks that can be modified by neuroinflammation.

38

Figure 3.2.1

Figure 3.2.1 Behaviour during noninflammatory conditions
Experiments shown in figures F, G, and H were performed by Sara Matovic.
(A) Design of study to investigate behaviour and neurochemical responses of Cx3cr1CreERhM3Dq mice under baseline noninflammatory conditions. CNO or vehicle (0.5% DMSO) (1.0
39

mg/kg) was injected 30 minutes before each behavioural task. (B) B-C) Total distance travelled
and time spent in the center in open field assessment on two consecutive days. D) Time spent
investigating a caged juvenile in 3-chamber social preference task. E) Time spent interacting
with a caged intruder in home cage. A new intruder is introduced in trial 5. 1 trial = 5 mins. F)
Time spent in light side of light-dark box (LDB). G) Time spent in the open arm of an elevated
plus maze. H) Total time of immobility in forced swim test (FST). Data represents 2-6 min. I)
Time spent sniffing enclosed vanilla scent. A new scent (caramel) was introduced for trial 5. J)
Time spent investigating a novel object. A new object was introduced for trial 5. All data was
analyzed using two-way ANOVA or student’s t-test. For two-way ANOVA, sidak’s post hoc
analysis was used.
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Previous literature supports a role of microglia Ca2+ signalling in modulation of
neuroinflammation and cytokine expression in the brain (Hoffmann et al. 2003; Tvrdik and
Kalani 2017). Therefore, in order to determine the effect of microglia Ca2+ signalling on gene
expression in the brain, with a new cohort of mice we used qPCR measurement to analyze
expression of cytokines and select genes in the hippocampus of mice 2 hours after the fourth
consecutive CNO (1 mg/kg) treatment (Day 4-shown in Fig. 3.3.2K-U). As a start, we focused
on hippocampus as accumulating data indicate the importance of hippocampus in social memory
(Okuyama 2018)which is affected during inflammation/sickness behavior (Czapski, Gajkowska,
and Strosznajder 2010). However, we did collect tissue samples from other brain areas including
the prefrontal cortex, amygdala and hypothalamus: these samples will be analyzed in the future.
Interestingly, cytokines have been implicated in neural plasticity in the hippocampus. For
example, low levels of proinflammatory cytokines expression appears to be necessary for LTP
induction in non-inflammatory condition (McCusker and Kelley 2013) whereas high levels of
proinflammatory cytokines can impair memory (Rogers et al. 2011).
hM3Dq induced microglia Ca2+ signalling did not alter mRNA expression of classic
proinflammatory cytokines TNFα, IL-6, or IL-1β (Fig. 3.3.2K-M). Nor did it alter gene
expression of other target genes, including iNOS, COX-1, COX-2, BDNF, or IL-1RA (Fig.
3.3.2N-R). There was also no effect of microglia Ca2+ signalling on mRNA expression of C1Q,
or IGF1 (not shown). In a control experiment, we found no effect of CNO on mRNA expression
of TNFα, IL-6, or IL-1β in the spleen of this same cohort of mice (Fig. 3.3.2S-U).
We next examined the effects of microglial hM3Dq activation on synaptic transmission using
whole-cell patch clamp electrophysiology in brain slices prepared from Cx3cr1CreER-hM3Dq
mice. Acute CNO treatment of brain slices did not change either the frequency (t-test(10)=0.5452,
p=0.5976) or amplitude (t-test(10)=0.758, p=0.4659) of mEPSCs recorded from CA1 pyramidal
neurons (Fig. 3.3.2T,U). In conclusion, hM3Dq induced microglia Ca2+ signalling did not induce
any overt sickness behaviour in mice, neuroinflammatory gene alteration, nor did it trigger
changes to synaptic transmission in brain slices.
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Figure 3.2.2
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Figure 3.2.2 mRNA gene expression and synaptic transmission under noninflammatory
conditions
Experiments shown in figures S and T were performed by Sara Matovic of the Inoue lab. (Fig.KR) qPCR measurements of mRNA expression of select genes in the hippocampus 2 hr after CNO
or vehicle: TNFα (p=0.223), IL-6 (p=0.376), IL-1β (p=0.256), iNOS (p=0.213), COX-1
(p=0.894), COX-2 (p=0.176), BDNF (p=0.253), IL-1RA (p=0.980). (Fig. S-U) qPCR
measurements of mRNA expression of select genes in the spleen 2 hr after CNO or vehicle:
TNFα (p=0.577), IL-6 (p=0.197), IL-1β (p=0.117). (V,W) Single-cell patch clamp recordings of
IE (ms) (V) and sEPSC amplitude (W) in Vehicle and CNO treated Cx3cr1CreER-hM3Dq cells.
All data shown are tamoxifen injected Cx3cr1CreER-hM3Dq mice. Data are represented as mean
+/- SEM, and analyzed using student’s t-test. The same mice were used for analysis of
hippocampus and spleen tissue. Reduced n values from the spleen are a result of technical failure
during RNA extraction.
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3.3 Stimulation of Ca2+-signalling in microglia attenuates LPSinduced sickness-like behaviour and upregulation of
proinflammatory cytokines in the brain
The results described above collectively showed that, under physiological conditions,
activating microglial hM3Dq Ca2+ signalling causes no overt changes in sickness-related
behaviors. During inflammation, on the other hand, microglia has long been thought to play roles
in sickness behavior as cellular intermediates that respond to inflammatory stimuli and signal to
neurons (Robert Dantzer et al. 2000; Konsman, Parnet, and Dantzer 2002). Thus, we next tested
whether microglial Ca2+ activation would modulate mouse behavior following systemic LPS
administration (100 μg/kg, i.p.), a model of systemic inflammation that drives sickness behavior
(Berg et al. 2004).
We initially stimulated microglia hM3Dq with CNO (1 mg/kg) for 4 consecutive days
and then challenged mice with LPS on day 4, prior to behavioural assays during expected time of
sickness (Fig. 3.4.1A). The animals decreased their body weight following LPS treatment (Fig.
3.4.1B; effect of Day: F(2,40)=59.64, p<0.0001), suggesting LPS triggered the previously reported
anorexic response (Robert Dantzer et al. 2008). However, weight loss was not affected by CNO
(F(1,20)=0.02686, p=0.8715) nor there was interaction between day and treatment (F(2,40)=1.098,
p= 0.3434). Social withdrawal is characteristic of sickness behaviour, so we repeated social
preference test 2 h or 24 h after LPS treatment. We selected these time points based on previous
study showing that social withdrawal is most prominent within the first 12 h after LPS (Corona
et al. 2010) and normal social interaction is restored 24 h after LPS injection.
Control mice showed reduced interaction with the social stimulus at 2 h, but investigation
times returned to baseline levels observed prior to LPS treatment at 24 h (Fig. 3.4.1C).
Interestingly, mice treated with CNO (1 mg/kg) did not present social withdrawal at 2 after LPS
treatment (Fig. 3.4.1C). There was a significant effect of CNO on social investigation
(F(1,20)=8.946, p=0.0072) and of time after LPS injection (F(1,20)=5.469, p= 0.0299), but there was
no interaction (F(1,20)=1.318, p= 0.2646). CNO-treated mice spend significantly longer time in
social interaction than vehicle mice when examined at 2 h (p=0.0093), but not at 24 h (p=0.2737)
after LPS injection. These results indicate that the activation of microglial hM3Dq signaling
attenuated LPS-induced reduction of social interaction. After completion of social preference,
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the same cohort of animals were immediately assessed in open field (shown in 24 h time point).
This time point was chosen based on previous research suggesting the peak LPS-induced
hypoactivity does not occur until 24 h after treatment (Corona et al. 2010). We found that CNO
attenuated LPS-induced hypoactivity (Fig. 3.4.1D; t-test(20)= 2.107, p=0.0479). There was a trend
in favour of CNO-treated animals spending more time in the center compared to vehicle-treated
animals, however this was not significant (Fig. 3.4.1E; t-test(20)= 2.06, p=0.0527). Overall,
activation of hM3Dq signalling in microglia attenuated some, but not all symptoms of sickness
behavior.
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Figure 3.3.1

Figure 3.3.1 Microglial hM3Dq activation by CNO alleviated LPS-induced sickness
behaviour
A) Design of study to investigate behaviour of Cx3cr1CreER-hM3Dq mice following LPS (0.1
mg/kg i.p.). B) Body weight following LPS for all animals in experiment shown. (n=11, per
treatment). C) Total time spent investigating a caged juvenile intruder in a 3-chamber apparatus.
Behaviour 2h and 24h after acute LPS injection shown. D,E) Locomotor activity (D) and total
time spent in center (E) in an open field assessment 24 hr after LPS (completed immediately
following 3-chamber social preference task). All data are represented as mean +/- SEM, *
p<0.05, ** p<0.005, means are significantly different from each other. All data was analyzed
using two-way ANOVA with sidak’s post hoc, or student’s t-test.
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Microglia may contribute to sickness behaviour by stimulating de novo expression of
inflammatory genes in the brain (Konsman, Parnet, and Dantzer 2002) (Biesmans et al. 2015;
Karman et al. 2006; Matyszak 1998; Skelly et al. 2013). Thus, we hypothesized that the
attenuattion of LPS-induced sickness behaviour by microglial hM3Dq activation could be
paralleled by changes in inflammatory gene expression. To test this, we examined mRNA levels
of various inflammatory genes in the hippocampus using qPCR in CNO and vehicle-treated mice
at 2 h after LPS or saline injection (Fig. 3.4.2F). Pre-treatment with CNO significantly attenuated
LPS-induced gene expression of TNFα (t-test, p=0.0061, Fig 3.4.2G), IL-6 (t-test, p=0.0200),
and IL-1β (t-test, p= 0.0121, Fig 3.4.2I). In contrast, CNO-treated animals did not show altered
expression of other inflammatory-related genes, including iNOS (Fig. 3.4.2J: p=0.6884), COX-1
(Fig. 3.4.2K: p=0.8589), COX-2 (Fig. 3.4.2L: p=0.1978), BDNF (Fig. 3.4.2M: p=0.7615), or IL1RA (Fig. 3.4.2N: p=0.1933). C1Q and IGF1 mRNA expression was also not altered by CNO
after LPS treatment (data not shown). These qPCR data suggests that CNO triggered a Ca2+
dependent selective anti-inflammatory effect, as not all genes were affected.
We also examined mRNA expression of TNFα, IL-6, and IL-1β in the spleen (Fig 3.4.2O-Q),
a major reservoir of peripheral monocytes (Swirski et al. 2009), collected from the same mice
examined for brain inflammatory responses. We found that CNO did not alter LPS-induced
levels of IL-6 (p=0.1090) or IL-1β (p=0.1480). However, CNO did significantly attenuate LPSinduced expression of TNFα mRNA in the spleen (p=0.0181). As an additional readout for
peripheral inflammatory response, we also analyzed levels of IL-6 in plasma in response to LPS,
using ELISA (Fig. 3.4.2R). IL-6 levels in peripheral circulation were not altered by CNO (t-test,
p=0.1781). In the absence of LPS, average levels of IL-6 were near the threshold of detection for
both vehicle (17.808 pg/ml) and CNO treated mice (33.592 pg/ml). These results suggest that
microglia Ca2+ signalling affects mainly the synthesis of cytokines in the brain after LPS
injection, with exception of TNF.
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Figure 3.3.2

Figure 3.3.2 Microglial hM3Dq activation by CNO alleviated LPS-induced
neuroinflammation
F) Design of study to investigate gene expression in hippocampus/spleen of tamoxifen treated
Cx3cr1CreER-hM3Dq mice after LPS. G-L) qPCR measurements of mRNA expression of select
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genes in the hippocampus 2 hr after LPS: TNFα (p=0.006), IL-6 (p=0.020), IL-1β (p=0.012),
iNOS (p=0.690), COX-1 (p=0.859), COX-2 (p=0.198), BDNF (p=0.762), IL-1RA (p=0.193). R)
ELISA measurement showing plasma IL-6 levels 2 h after LPS. O-Q) qPCR measurements of
mRNA expression of cytokines in the spleen 2 hr after LPS: TNFα (0.043), IL-6 (0.130), IL-1β
(0.101). All data are represented as mean +/- SEM. All data was analyzed using student’s t-test,
p<0.05, **= p<0.005. Hippocampus, spleen, and plasma data are from the same mice. Reduced
n values (spleen data) are a result of technical failure during RNA extraction.
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3.4 CNO does not affect LPS-induced neuroinflammatory
response in the hippocampus of wildtype mice
While CNO is believed to specifically act on DREADDs, few studies have reported nonspecific effects of CNO and/or its metabolites clozapine and N-desmethylclozapine (Gomez et
al. 2017; MacLaren et al. 2016; Manvich et al. 2018). To test whether the effect of CNO we
observed in cytokines depended on DREADD expression, we repeated the LPS x CNO
experiments in control mice and examined cytokine mRNA levels in the hippocampus 2 hr after
LPS (0.1 mg/kg, i.p.) injection (Fig. 3.5A). We detected significant effects of LPS in
upregulating mRNA for IL-1β (Fig. 3.5B; F(1,24)=12.33, p=0.0018), IL-6 (Fig. 3.5C; F(1,24)=6.15,
p=0.0205), and TNFα (Fig. 3.5D; F(1,24)=11.3, p=0.0026). In these control mice CNO had no
effect on LPS-induced mRNA expression (IL-1β: F(1,24)=0.1825, p=0.6730; IL-6: F(1,24)= 0.027,
p=0.8686; TNFα: F(1,24)= 0.2964, p=0.5912). These results support the interpretation that CNO
does not affect LPS-induced cytokine synthesis in the absence of hM3Dq expression. Moreover,
control experiments using 1 mg/kg of CNO did not reveal any effects on behavior tests in mice
not expressing DREADDs (not shown), consistently with the lack of changes in behavioral
parameters in the absence of LPS injection.
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Figure 3.4

Figure 3.4 CNO did not alter cytokine expression in hippocampus of wildtype mice
A) Design of study to investigate mRNA expression in hippocampus of wildtype mice. B-D)
qPCR measurement of mRNA expression of IL-1b, IL-6, and TNF-α in hippocampus of wildtype
mice 2 hr after LPS. Data are represented as mean +/- SEM, and analyzed using two-way
ANOVA with sidak’s post hoc analysis.
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3.5 CNO or LPS did not alter microglia morphology
Morphology of microglia is widely used as a marker for activity changes of microglia
(Madore et al. 2013), including after systemic LPS injection (Hines et al. 2013, 4). To gain
further insight how CNO altered LPS-induced microglia activation, we examined the changes in
microglial morphology using immunohistochemistry for Iba-1, a microglia/macrophage-specific
calcium-binding protein commonly used to label microglia (Madore et al. 2013). As illustrated in
Fig 3.4.1A, a cohort of mice used for the behavioral study after LPS/CNO injections were further
challenged with a higher dose of LPS (500 µg/kg, i.p.) with or without pre-treatment of CNO and
sacrificed 48hr later for histology. We found that CNO, LPS, or the combination of both had no
effect on microglia area of process coverage (arborisation) (Fig. 3.6C, F=(3,11)=0.776, p= 0.531)
or soma size (Fig. 3.6D, F=

(3,11)=0.584,

p= 0.640) compared to baseline microglia. The

morphological index was also similar between treatment groups (Fig. 3.6E, F=(3,11), p= 0.995).
These data suggest that LPS, at the dose used in this study, did not initiate detectable
morphology changes in microglia in the CA1, and CNO alone or in combination with LPS did
not alter microglia morphology.
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Figure 3.5

Figure 3.5 CNO or LPS did not alter microglia morphology
A) Timeline of study to investigate microglia morphology following CNO and/or LPS. Note 1 st
LPS injection is (0.1 mg/kg), 2nd LPS injection is (0.5 mg/kg). B) Representative Evos images
from hippocampus of tamoxifen treated Cx3cr1CreER-hM3Dq mice following treatment of
Vehicle/LPS or CNO/LPS. C-E) Quantification of total microglia process coverage
(arborisation), cell body size (soma), and ratio between arborisation and soma (morphological
index) using image J software. Data are represented as mean +/- SEM. Note each dot = avg. of
20 cells. All mice represented completed behaviour series one before subsequent LPS injection
on day 7 (see timeline).
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Chapter 4
4. Discussion
Microglia sense exogenous and endogenous inflammatory signals, and orchestrate
subsequent neuroinflammation that is central to sickness behaviour. Accumulating evidence
indicate that the reactivity of microglia to inflammatory stimuli is labile, influenced by the
history of their previous activities and the current status of the brain. Sensitization may underlie
vulnerability to subsequent insults (Niraula, Sheridan, and Godbout 2017). The key finding of
this project was that chronic activation of hM3Dq- signalling in microglia attenuates microglial
reactivity to LPS-induced systemic inflammation, alleviating the production of proinflammatory
cytokines in the brain and ensuing sickness behaviour.

4.1 CX3CR1CreER mice to genetically manipulate microglia
To study the consequence of Gq-type GPCR signaling in microglia in vivo, we generated
CX3CR1CreER -hM3Dq mice,

microglia/monocyte specific promoter CX3CR1 drives the

expression of hM3Dq expression in a tamoxifen-inducible and Cre-dependent manner (Parkhurst
et al. 2013). CX3CR1 + monocytes rapidly turnover (0.1 %/hour) from a CX3CR1 - bone marrow
precursor population and exhibit near complete turnover after 30 days (Fogg et al. 2006),
whereas the turnover of CX3CR1+ microglia is substantially slow (0.2%/day in the
hippocampus, 0.075% in the cortex)(Tay et al. 2017) Thus > 1 month after tamoxifen injection,
hM3Dq is expected to be present only in microglia.
We found that 96.3% of Iba1 cells were labelled by HA-tagged hM3Gq, and 87% of HA cells
were Iba-1 positive. This is comparable with previous use of CX3CR1CreER mice to genetically
manipulate microglia, which showed (98.8% +/- 1.3%) co localization of CreER-dependent
expression of EYFP and microglia marker Iba1 (Parkhurst et al. 2013). In line with the low
turnover rate of microglia (Lawson, Perry, and Gordon 1992), the expression of HA epitope tag
was strong from 3 months up to 1 year after tamoxifen injection. It should be noted that
microglia turnover rate is higher in the olfactory bulb, hippocampus, and cerebellum, compared
to cortex, midbrain, and hypothalamus (Tay et al. 2017). However, even the most rapid turnover
rates (8 months in the olfactory bulb and 15 months in the hippocampus) are well beyond our 3
month time period post tamoxifen.
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Microglia proliferation is maintained by coupled proliferation of resident microglia rather
than infiltration of bone-marrow-derived immune cells (Askew et al. 2017). That being said, it
should be noted that during pathological conditions like traumatic brain injury and ischemic
brain injury, Alzheimer’s disease, prion disease, and multiple sclerosis, the BBB often becomes
compromised and infiltration of bone marrow-derived immune cells becomes common (GomezNicola and Perry 2015; Brown and Neher 2014; Hanisch and Kettenmann 2007). Thus, studies
attempting to characterize microglia-DREADD dynamics in pathological conditions must take
this into consideration. Indeed, microglia dynamics have recently been elegantly investigated by
Tay and colleagues, who employed a multicolor fluorescence fate mapping system allowing for
identification of specific mechanisms of turnover rates, which differ by brain region and
subpopulations of microglia (Tay et al. 2017). This too also acknowledges the necessity to
account for differences in steady state and disease. In this project, we do not consider BBB
integrity to be an issue, since the low dose of LPS (100 μg/kg) we used does not compromise the
BBB integrity (Banks and Robinson 2010; Salam, Pariante, and Zunszain 2017).

4.2 Microglia Gq signalling in healthy conditions
By using the above described strategy to express hM3Dq in microglia, we found that a
sub-chronic stimulation of microglial hM3Dq signalling with systemic injections of CNO for 3
consecutive days did not elicit any detectable behavioral changes, including social behaviour,
locomotor activity, anxiety and stress-related behaviour, or recognition and olfaction, that are
relevant to sickness behavior (Robert Dantzer and Kelley 2007; Skelly et al. 2013). In line with
the lack of behavioral change, we also did not detect significant changes in the mRNA levels of
cytokines (IL-1β, IL-6, TNFα) and other inflammatory genes (COX-1, COX-2, iNOS, BDNF,
IL-1RA) and genes not shown (C1Q, IGF-1) in the brain after 3 daily CNO injections. Taken
together, we concluded that the activation of microglial hM3Dq signalling does not cause
classical neuroinflammatory response.
While microglial hM3Dq stimulation did not cause neuroinflammation, it is still possible
that other aspects of microglial function maybe affected that were not detected by our array. Gq
signaling resulting from hM3Dq activation leads to an elevation of intracellular calcium as
predicted from canonical Gq signaling as well as confirmed by our own in vitro assay. It has
been shown that Cx3Cr1 receptor signaling, which also elevates intracellular Ca2+ levels,
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contributes to modulation of AMPA receptor function at active glutamatergic synapses
(Ragozzino et al. 2006). Similarly, dysregulation of fraktalkine signalling decreases hippocampal
neurogenesis (Bachstetter et al. 2011), and also alter synaptic plasticity mechanisms (e.g. LTP
and LTD) (Bertollini et al. 2006). Related to this, it is worth noting that cytokines, such as IL-1β,
are expressed at low levels under physiological conditions and are believed to contribute to
synaptic plasticity, learning and memory (Raz Yirmiya and Goshen 2011). Pharmacological
blockade of IL-1 receptor has been shown to impair hippocampal-dependent learning tasks (R.
Yirmiya, Winocur, and Goshen 2002). Further studies are required to understand potential
consequences of microglial hM3Dq-signaling under physiological conditions.
A recent study showed that the activation of hM3Dq expressed in spinal microglia under
CD68 (microglia/macrophage) promoter induced allodynia, which was abolished by intrathecal
administration of IL-1 receptor antagonist in rats (Grace et al 2018). Along the same line, BV2
cells (microglia cell line) stably expressing hM3Dq respond to CNO with an upregulation of
inflammatory cytokines including IL-1β (Grace et al 2018). This pro-inflammatory consequence
of hM3Dq signaling in certain types of microglia is not in line with our results. However,
important differences between this and our studies is the promotor used to drive hM3Dq
expression. CD68 promoter used by Grace et al (2018) to drive Cre expression drives Cre not
only in microglia by also by perivascular and meningeal macrophages in the brain, and its
expression is upregulated by inflammatory stimuli such as LPS (Papageorgiou et al. 2016, 4)
whereas the CX3CR1 promotor is specific to microglia in the brain). It is therefore possible that
hM3Dq is expressed in different populations of cells in the two studies providing a plausible
explanation for the different consequences of hM3Dq signaling. Furthermore, our observation of
CX3CR1CreER-hM3Dq mice during injection protocols and behavioural experiments suggests
mice did not experience discomfort. We did not detect any changes in baseline behaviour in
CNO treated animals, and no abnormalities during open field or social interaction were detected,
which is an indicator of pain (Kolstad et al. 2012). Moreover, Grace et al. used adeno-associated
virus and drove hM3Dq expression under CD68 promotor activity in rats. Caution is warranted
when generalizing molecular and functional responses of microglia between species (rat versus
mice). For instance, network differences in chemokine and cytokine expression in mice
compared to rat brain have been identified following oxygen-glucose deprivation (Du et al.
2017). Furthermore, microglia markers including Iba1, CD11b, and CD68 differ between species
56

during activation states (Lam, Lively, and Schlichter 2017). This makes it an important
consideration since both the referenced study and the present study used LPS to provoke
inflammation.
The use of adeno-associated virus is another important difference, since microglia are
immune cells and are known to respond to viral infection (Sakurai et al. 2008). Our mouse model
drives hM3Dq expression under CAG promoter (following Cre-dependent removal of floxedSTOP cassette), resulting in stable hM3Dq expression that is insensitive to inflammatory
signaling. For these reasons, we speculate that the differences between these two studies are due
to difference in the population of cells that express hM3Dq.

4.3 LPS-induced sickness behaviour
In contrast to stimulation of microglia hM3Dq under physiological conditions,
stimulation of microglia hM3Dq for 4 consecutive days prior to LPS-challenge attenuated the
development of sickness behavior as evidenced by the amelioration of social withdraw and
decrease in open field locomotor activity. The attenutation of sickness behavior was paralleled
by the decrease of LPS-induced upregulation of brain cytokine levels including IL-1β, IL-6 and
TNFα, indicating that sub-chronic activation of microglial hM3Dq signaling prior to LPSinduced systemic inflammation altered neuroinflammatory response.
Of interest is the finding that this priming effect is rather specific to certain aspects of
neuroinflammatory response, because CNO treated mice still showed an intact anorexic response
(body weight loss) to LPS. Similarly, LPS-induced upregulation of COX-2 and mPGES-1, two
key enzymes necessary for PGE2 synthesis, were not affected by CNO treatment. Together,
these findings are in line with previous findings that administration of COX-2 inhibitors blocks
the anorexic response in LPS-treated mice and rats (Johnson et al. 2013; Pecchi et al. 2009; Jin et
al. 2016), and that COX-2 KO mice are resistant to LPS-induced anorexia (Nilsson et al. 2017).
Conversely, inflammation-induced hypoactivity persists in mice with selective deletion of COX2 and mPGES1 in brain endothelial cells, but these mice lack typical fever response (Wilhelms et
al. 2014). One potential explanation for the lack of effect on COX-2 mediated anorexia is
microglia express little or no COX-2 after immune challenge (Engström et al. 2012). Meanwhile,
other cell types are involved in COX-2 production during LPS-induced systemic inflammation
(via synthesis of PGE2), including neurons, astrocytes, and endothelial cells (Shiow et al. 2017,
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2017). While the precise contribution of each cell type, including microglia, to anorexia remains
to be identified (Nilsson et al. 2017), this particular finding provides clues as to the specific
mechanisms behind the characteristic wasting of body weight. Indeed, based on this negative
finding, we would also not expect to see an effect of microglia hM3Dq-signalling on fever,
cortisol release, hyperalgesia, or lethargy, since these LPS-stimulated inflammatory responses
are also regulated by prostaglandin/COX signalling. These data suggest that microglial hM3Dq
signaling, or microglia-dependent inflammatory response, contribute to some but not all aspects
of sickness behavior.
Future studies are warranted to dissect out specific inflammatory and downstream neural
mechanisms contributing to specific aspects of sickness behavior. For instance, whether
microglia hM3Dq signalling modulates LPS-induced depressive behaviour awaits future study.
There is evidence of a dissociation between sickness and depressive-like behaviours triggered by
systemic inflammation. Depressive-like behaviour, indicated by increased time of immobility in
forced swim tests (FST) and tail-suspension tests (TST), remain after food intake and locomotor
activity have returned to baseline (O’Connor et al. 2009)(Salazar et al. 2012; Dinel et al. 2014).
It is speculated that depression develops in response to immune challenge once the initial
sickness response has been prolonged (Robert Dantzer et al. 2011; Liu et al. 2013; Moreau et al.
2008). The kynurenine pathway is likely to play an important role in LPS-induced depressive
behaviour, LPS-induced cytokines activates the kynurenine rate-limiting enzyme indoleamine
2,3-dioxygenase (IDO), which parallels development of depressive-like behaviour (Moreau et al.
2008) (Salazar et al. 2012; Dinel et al. 2014; O’Connor et al. 2009; Fu et al. 2010; Liu et al.
2013; Meier et al. 2016). Since IDO activity is focused in activated monocytes and microglia
(Moroni et al. 1991) our microglia-DREADD mouse is a promising tool to investigate LPSinduced depressive behaviour in future studies.

4.4 Inflammatory Cytokines, and Microglia priming
Sickness behavior is at least in part dependent on microglia and brain cytokines (Henry et
al. 2008). TNFα and IL-1β are necessary for sickness behaviour, while IL-6 is required for the
febrile response to LPS (Robert Dantzer et al. 2008). Indeed, it is predicted that TNFα, IL-1β,
and IL-6 alter behaviour by direct actions on neurons (Poon et al. 2015). Microglia are primary
producers of proinflammatory cytokines, and inhibiting their inflammatory responses with
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minocycline abolishes sickness behaviour and cytokine response to LPS (Henry et al. 2008).
Accordingly, we report a substantial attenuation of microglial-regulated cytokine synthesis by
subchronic activation of hM3Dq signaling. We found that the LPS-induced increase in mRNA
for TNFα, IL-6, and IL-1β was attenuated in CNO treated animals. The difference in CNO
effects in healthy vs. inflammatory conditions points to the importance of understanding
modulatory, rather than stimulatory, effects of hM3Dq signalling. For example, it has been
shown that pharmacological activation of metabotropic glutamate receptor 5, Gq-type GPCR,
reduced microglia activation in response to LPS, marked by reduced ROS, nitric oxide, and
TNFα production in primary microgial culture (Byrnes et al. 2009).
The modulation of microglial functions, such as their sensitivity to inflammatory
response, is an important topic with relevance to aging, neurodegeneration and traumatic brain
injury (TBI). There is clear evidence of elevated baseline brain inflammation with age in both
rodents and humans, where microglia likely play important roles (Fenn et al. 2013; J. P. Godbout
et al. 2005; Henry et al. 2009). In the context of systemic inflammation, intraperitoneal (i.p.)
administration of LPS triggers a prolonged and exaggerated neuroinflammatory response in aged
mice compared to young adult controls (Wynne et al. 2010). Importantly, the elevation of
cytokines is unique to the brain, and not present in plasma in aged animals (Barrientos et al.
2006), suggesting priming likely occur at the level of the brain. In line with this idea, microglia
in the aged brain show elevated levels of inflammatory markers, such as MHC II, and produce
higher levels of IL-1β in response to inflammatory stimuli (Henry et al. 2009).
Animal models of neurodegeneration, particularly prion disease and AD, also show
markers of microglia priming including elevated MHC ll and CD68 expression (Cameron and
Landreth 2010; Cunningham et al. 2005). Mice models of presymptomatic prion disease
displayed heightened inflammatory response and neuronal death to i.c. and i.p. LPS, compared to
non-prion controls (Cunningham et al. 2005). Systemic LPS caused significant increase in IL-1β
in transgenic AD mice compared to non-transgenic controls, and this significantly contributed to
pathology (Krstic et al. 2012; Sly et al. 2001). Indeed, a recent study suggests microglia use
epigenetic mechanisms that reprogram their responses to neurodegeneration and inflammation.
Pathological and inflammatory responses to onset of Aβ deposition or stroke pathology were
exacerbated in animals that were previously exposed to acute LPS injection (Wendeln et al.
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2018). This immune training effect was inhibited when Tak1 or Hdac1/2 were knocked out, two
primary genes responsible for epigenetic mechanisms in microglia network (Datta et al. 2018;
Goldmann et al. 2013). In contrast, consecutive doses of LPS (4X) induced a tolerance effect,
whereby the inflammatory response to Aβ deposition or stroke pathology is attenuated (Wendeln
et al. 2018), similarly to our study. Indeed, other studies support the possibility of an alternative
tolerance effect to consecutive doses of LPS (Norden et al. 2016; Fukushima et al. 2015). The
differential mechanisms behind these opposing responses is unclear.
The literature on microglia priming suggests that the modulation of their reactivity to
inflammatory stimuli is not unique to specific pathologies. Rather, microglia priming is affected
by any brain tissue injury which triggers an inflammatory cascade, suggesting it is cytokines and
the molecular signals of inflammation that prime microglia. Accordingly, the spectrum of stimuli
that invokes microglia priming is extended to traumatic brain injury, which triggers prolonged
microglia activation in animal studies (Loane et al. 2014; Ziebell et al. 2012). This prolonged
activation further sensitizes microglia for subsequent inflammatory stimuli. Indeed, repeated
blows to the head may also sensitize microglia to inflammation; the initial blow provides the
priming, while subsequent blows lead to elevated inflammatory responses (Weil, Gaier, and
Karelina 2014). Both astrocytes and microglia presented an inflammatory phenotype up to at
least 12 months after repeated blows, compared to 6 months after a single TBI (Mouzon et al.
2014). Indeed, numerous and consecutive head traumas has been linked to the neurodegenerative
disease chronic traumatic encephalopathy (CTE) (Petraglia et al. 2014).
Microglia reactivity may also have relevance for neuropsychiatric disorders. For instance,
there is evidence of depressive like disturbances following systemic immune challenge, which
are more pronounced in aged compared to young adult control mice (Corona et al. 2010;
Jonathan P. Godbout et al. 2008; Kelley et al. 2013). Depressive symptoms are exacerbated in
other inflammatory conditions, including ageing and obesity (Penninx et al. 2003; Milaneschi et
al. 2009). Furthermore, human patients with hepatitis C or cancer that receive cytokine
immunotherapy using interferon-alpha (IFNα) or IL-2 commonly experience symptoms of
depression (Capuron et al. 2002, 2004). The finding that pharmacological blockade of cytokines
improves symptoms independent of the clinical prognosis (Tyring et al. 2006) supports the link
between inflammation and the neuropsychiatric cases of depression.
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Overall, priming of microglia and their hyper-activation under inflammatory conditions
contributes to and amplifies the neurodegenerative processes. However, a dichotomy exists
where inflammatory stimuli may also induce tolerance in microglia, and attenuate subsequent
inflammatory responses. This makes microglial priming an important research focus in the field
of neurodegeneration.

4.5 Cellular mechanisms downstream of hM3Dq
A major consequence of Gq-signaling is an elevation of intracellular Ca2+, and our in vitro
study validated that microglial hM3Dq triggers the expected Ca2+ elevation. The role of
microglial Ca2+ signaling remains largely unknown and likely play diverse functions. With
relevance to inflammation, it has been shown that a single stimulation with LPS leads to a long
lasting elevation of calcium concentration in cultured microglia (Hoffmann et al. 2003) and a
calcium chelator BAPTA prevents LPS-induced release of TNFα, IL-6, and nitric oxide
(Hoffmann et al. 2003). Recent imaging studies using multi-photon microscopy revealed an
interesting microglia calcium dynamics in vivo. Microglia display no spontaneous calcium
transients under non-inflammatory conditions, but large calcium transients were induced by
rupturing a single cell membrane within close proximity to microglia (Eichhoff, Brawek, and
Garaschuk 2011).
Interestingly, microglia response to laser burn injury showed 67% of microglia responding
towards the lesion displayed calcium transients in LPS-primed brains, which was significantly
higher than laser injury in non-LPS treated brains (Pozner et al. 2015). Data from Alzheimer’s
models is in agreement with this, since microglia within close proximity to plaques shows
elevated calcium transients (Brawek et al. 2014), and microglia isolated from postpartum brains
of Alzheimer’s patients revealed microglia cells with elevated resting calcium levels and reduced
response to ATP (Veerhuis, 2005), a result later confirmed in vivo (Brawek et al. 2014). An
interesting question is the localization of hM3Dq signalling in microglia. hM3Dq appeared to co
localize with Iba1+ microglia primarily in the processes (see Figure 3.2.2). This supports existing
in vivo data showing calcium transients in microglia in response to LPS are primarily localized to
the processes

Indeed, spontaneous calcium activity in microglia was increased 8-fold in

response to injection of LPS (Figure 4.2), compared to baseline, and >80% of transients were
localized to the processes.
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How exactly calcium signalling regulates microglia reactivity to inflammatory stimuli
remains to be studied, but our finding suggests microglia-DREADD mice will be useful to
dissect these mechanisms.

4.6 Microglia-hM3Dq influence on peripheral inflammation
Systemic administration of LPS is widely used to induce inflammatory response both in
the periphery and in the brain. LPS is a large, hydrophilic molecule that does not cross the BBB,
and the dose use used in this study (100 μg/kg) is unlikely to compromise the integrity of the
BBB (Banks and Robinson 2010). A large body of studies have established that microglial
activation is the result of peripheral cytokines signaling to the brain (Robert Dantzer et al. 2000).
Accordingly, we measured plasma IL-6 levels, as an indicator for the magnitude of peripheral
inflammation, and found that CNO treatment did not affect LPS-induced plasma IL-6 levels.
Furthermore, we found that LPS-induced upregulation of mRNA for IL-6 and IL-1β in the spleen
was not altered by hM3Dq activation in microglia. These data indirectly validate that peripheral
monocytes that express CX3CR1 do not express hM3Dq (as predicted by the design of our
mouse model) or if any hM3Dq activation in these peripheral monocytes does not substantially
alter LPS-induced systemic inflammation. Importantly however, we found that levels TNFα
mRNA in the spleen was attenuated in CNO-treated mice (despite the lack of change in IL-1β
and IL-6 levels). One possible explanation for this isolated effect is that activation of microglial
hM3Dq signalling in the brain may subsequently affects specific aspects of the peripheral
inflammatory response via nerve outputs (Tracey 2009). This speculation is based on the notion
that the brain regulates immune activities via both sympathetic and parasympathetic outflows.
For example, stimulation of the vagal efferents strongly inhibit production of TNFα and protects
animals from LPS-induced endotoxic shock, a mechanism known as the cholinergic antiinflammatory reflex (Borovikova et al. 2000). Chemokine induction by active microglia also
transmits neuroinflammatory signals to the periphery and may represent a mechanism by which
resident microglia signal to peripheral immune cells (Carson et al., 2006; Cazareth et al., 2014;
Fenn et al., 2014b; Puntambekar et al., 2011; Wohleb et al., 2013). Future research should
characterize peripheral inflammatory response in more detail as a potential downstream effects
of microglial modulation by hM3Dq.
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4.7 Microglia Morphology
A major characteristic of microglia change of function is often a change in morphology.
Microglia have been shown to acquire an ameboid morphology in response to inflammatory
stimuli (Madore et al. 2013; Kettenmann et al. 2011). We found that cell body size, arborisation,
and morphological index (Tremblay et al. 2012) were not altered by CNO in noninflammatory
conditions. This supports our behavioural findings that microglia Gq-stimulation did not induce
overt behavioural change, or mRNA expression of cytokines under healthy conditions. However,
we did not find an effect of CNO on microglia morphology during inflammatory conditions. One
possible explanation for this is that microglia morphological dynamics is not reactive to changes
in microglia calcium signalling. Indeed, microglia Ca2+ activity decreases at later stages of
inflammation, around 24 hr after LPS injection, but at this time point microglia morphology does
not change, and their ameboid structure persists (Milior et al. 2016; O’Connor et al. 2009). This
suggests morphology may not be sensitive to changes in calcium dynamics, which would
exclude this microglia property from hM3Dq influence. However, we also did not find an effect
of LPS on morphology. Previous studies have shown LPS-induced morphological changes to
microglia (Choi et al. 2012; Hines et al. 2013; Norden et al. 2016; Wohleb et al. 2012), but the
protocols used to analyze microglia morphology are inconsistent (Choi et al. 2012; Hines et al.
2013; G. Luheshi et al. 1996; Madore et al. 2013; Milior et al. 2016). Research also shows that
microglia shape exists along a continuum (Morrison et al. 2017; Town, Nikolic, and Tan 2005)
In other words, the exact number of quantifiable microglia morphology changes is unknown.
Thus, it is possible our chosen technique was not sensitive enough to the particular
morphological change in our unique mouse model. Furthermore, the dosage of LPS and time
point of analysis also varies across studies analyzing morphology and this is also likely to
influence the result (Furube et al. 2018; Madore et al. 2013). Considering the

roles of

endogenous microglia GPCRs in phagocytosis (Koizumi et al. 2007) future studies to assess the
morphology of microglia following inflammatory stimuli/hM3Dq signalling are are warranted.

4.8 Limitations
Our transgenic mouse model are heterozygous for CX3CR1CreER mice, in which knock-in
of CreER results in knock out of endogenous Cx3CR1. Thus, our study used CX3CR1+/- mouse
in all experiments and compared the effects of CNO versus vehicle. CX3CR1 receptor provides
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bidirectional neuron-microglia signalling, and has previously been shown to alter microglia
migration, hippocampal neurogenesis, pathology, and behaviour phenotypes (Bachstetter et al.
2011; Hoshiko et al. 2012; Milior et al. 2016; Rosa C. Paolicelli et al. 2011). Most of these
studies detected abnormality in homozygous KO CX3CR1

-/-

(Zanier et al. 2016; Zhan et al.

2014), and therefore, it is generally considered that heterozygous CX3CR1-/+ maintain normal
phenotype. Nevertheless, we cannot exclude the possibility of the influence of CX3CR1
heterozygosity on their response to LPS, CNO and interaction of both. Importantly, however, our
experiments were designed to compare DREADD activation among CX3CR1+/- hM3Dq
expressing mice. Thus, the effects of CX3CR1 deficiency, if any, should occur equally in CNO
and vehicle treated mice. It must be noted that experiments were only completed in young male
mice. Aged mice display primed microglia that display elevated inflammatory responses
(Niraula, Sheridan, and Godbout 2017), thus, the hM3Dq-mediated modulation of microglia
could be different in older mice. Second, there are notable differences between microglia and
neuroimmune signalling in the male and female brain throughout the lifespan (Lenz and
McCarthy 2015). For instance, qPCR validates that male and female microglia follow distinct
gene expression patterns after acute LPS challenge (Hanamsagar et al. 2015). Future studies
should attempt to replicate this experiment using female mice in order to determine if hM3Dq
modulation is different compared to in the male brain.
Microglia are not the only cell types known to synthesize cytokines in the brain. Astrocytes
also respond to LPS-induced inflammation by upregulating cytokines, albeit at a later time point
compared to microglia (Norden et al. 2016). It is unknown in the present study what the exact
contribution of astrocytes are for our measurements 2 hour after the injection of LPS. Hence the
partial attenuation of cytokine synthesis we observed might be related to the fact that our
approach only changed Ca2+ signalling in microglia. To this point, it has been suggested that
endogenous GPCRs expressed by microglia can modulate astrocyte neuroinflammatory
responses, and these are calcium dependant (Quintas et al. 2014). For instance, in LPS treated
co-cultures of astrocytes and microglia, UTP is rapidly converted into UDP, which activates
P2Y6 receptors, inducing the release of NO by microglia that causes astrocyte apoptosis, thus
controlling their rate of proliferation and preventing an excessive astrogliosis (Quintas et al.
2014). Furthermore, modulation of astrocytes has been shown to alter neuronal activity and
behaviour (Halassa and Haydon 2010). In another study, microglia signals in the form of IL-1α,
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TNFα, and C1q induced astrocytes towards a neurotoxic phenotype which contributed to
pathology (Liddelow et al. 2017). In a final example, in vitro studies suggest astrocytes, and also
endothelial cells, modulate microglia activation states. Astrocytes and endothelial cells were
subject to oxygen glucose deprivation, and their conditioned media were transferred to microglia.
Microglia exposure to conditioned media led to elevation of classic activation markers compared
to baseline, including proinflammatory cytokines and surface markers like CD11b, CD45, CD68,
MHC class II (Xing et al. 2018). These studies outline the bidirectional communication of
microglia and astrocytes and acknowledge the importance of considering these glia cells as well.
Future studies should investigate the specific contribution of astrocytes in sickness, and whether
they are potentially modulated by downstream microglia signalling. In line with this, we cannot
say how hM3Dq is actually modulating microglia activity.
Recent studies indicated that CNO itself is a relatively low affinity agonist for DREADDs and
that clozapine to which CNO converts to in vivo acts on DREADDs (Gomez et al. 2017;
MacLaren et al. 2016). Also it has been proposed that CNO poorly crosses the BBB and in vivo
efficacy of CNO requires its conversion to clozapine, which crosses the BBB. In previous in
vitro experiments performed by our lab in cultured microglia, CNO had very fast effects
consistent with direct activation of hM3Dq (as the culture setting lacks CNO metabolizing
enzyme). On the other hand, in wild-type mice that do not express hM3Dq, CNO alone did not
affect cytokine synthesis in response to LPS. Furthermore, our lab has completed behavioural
investigation in wildtype controls that lack DREADD expression and have found no effect of
CNO. While a few earlier studies reported non-specific effects of CNO, which came results from
the actions of clozapine, on some behavior, those studies used higher doses (2.0 – 20.0 mg/kg) in
comparison to the dose we used (1.0 mg/kg) (MacLaren et al. 2016; Manvich et al. 2018).
Another drug used in this study, tamoxifen, has been suggested to have side effects. Tamoxifen
is a selective estrogen receptor modulator (SERM) which binds to ERs and elicits either agonist
or antagonist activity depending on the tissue it is acting in (Patel et al. 2017). Since it is a potent
agonist in breast tissue, it has become a popular treatment for breast cancer. However, due to
these effects on the endocrine system, it has been implicated in reproductive dysfunction (Patel
et al. 2017), and likely effects bone mineral density (Vehmanen et al. 2006). In these studies,
mice treated with tamoxifen experienced acute weight loss of 3-6 grams. However, mice quickly
regained weight, and no additional side effects of tamoxifen were detected. Furthermore, all mice
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were injected with tamoxifen, suggesting any differences between vehicle and CNO treated
microglia-hM3Dq mice are not due to inadvertent effects of tamoxifen.

4.9 Conclusion
Whether the activation of Ca2+ by hM3Dq only in microglia can somehow desensitise
further LPS-induced Ca2+ signalling is an intriguing question that remains to be answered.
Regardless, we provide a proof of principle that specific regulation of GPCR signalling in
microglia is a powerful approach to regulate cytokine synthesis and sickness behavior. Our data
suggest that attenuation of cytokine synthesis by microglia can attenuate certain behavioral
aspects related to sickness. This new approach that avoids the use of virus to express hM3Dq in
microglia can open new avenues to understand how neurons communicate with microglia and
vice-versa in a number of other experimental settings, including during development and in
mouse models of neurodegenerative diseases.
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